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1 Abbreviations 
 
5HT2AR 
 
5-hydroxy-tryptamine-2A serotonin receptor 
AIDS 
 
acquired immune deficiency syndrome 
APCs 
 
antigen-presenting cells 
ASC  
 
apoptosis-associated speck-like protein containing a CARD 
at-NCCR 
 
archetype non-codin control region 
BKPyV 
 
BK polyomavirus 
BMDCs  
 
bone marrow-derived dendritic cells 
bp 
 
base pairs   
c-di-GMP 
 
cyclic diguanylate monophosphate 
cART 
 
combination antiretroviral therapy 
CMV 
 
cytomegalovirus 
CNS 
 
central nervous system 
CSF 
 
cerebrospinal fluid 
DAI 
 
DNA-dependent activator of IRFs 
DC 
 
dendritic cells 
DNA 
 
deoxyribonucleic acid 
EBV 
 
Epstein- Barr virus 
ER 
 
endoplasmic reticulum 
EVGR 
 
early viral gene region 
HA 
 
hemagglutination assay 
HAI hemagglutination inhibition assay 
HBV  hepatitis B virus  
 HC  hemorrhagic cystitis  
HIV 
 
human immunodeficiency virus 
HMGB  
 
high-mobility group box (proteins) 
HPyV10 
 
human polyomavirus 10 
HPyV12 
 
human polyomavirus 12 
HPyV6 
 
human polyomavirus 6 
HPyV7 
 
human polyomavirus 7 
HPyV9 
 
human polyomavirus 9 
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HPyVs 
 
human polyomaviruses 
HSCT 
 
hematopoietic stem cell transplantation 
HSV-1 
 
herpes simplex virus-1 
IFN interferon 
IRIS 
 
immune reconstitution inflammatory syndrome 
JCPyV 
 
JC polyomavirus 
KIR(s) 
 
killer-cell immunoglobulin-like receptor(s) 
KTR 
 
kidney transplant recipient 
LRO 
 
lysosome-related organelles 
LTag 
 
large T-antigen 
LVGR 
 
late viral gene region 
MCMV 
 
murine cytomegalovirus  
MCPyV 
 
Merkel cell polyomavirus 
mDCs  
 
myeloid dendritic cells  
MEFs 
 
mouse embryonic fibroblasts 
MHC 
 
major histocompatibility complex 
MITA  
 
mediator of IRF3 activation 
MRI 
 
magnetic resonance imaging 
mRNA 
 
messenger ribonucleic acid 
MS 
 
multiple sclerosis 
NCCR 
 
non-coding control region 
NK cells 
 
natural killer cells 
NLR(s) 
 
(NOD)-like receptor(s) 
NLS 
 
nuclear localization signal 
NOD 
 
nucleotide-binding oligomerization domain  
ORF 
 
open reading frame 
PAMPs 
 
pathogen- associated molecular patterns 
PBMCs 
 
peripheral blood mononuclear cells 
PCNA 
 
proliferating cell nuclear antigen 
pDCs 
 
plasmacytoid dendritic cells 
PML 
 
progressive multifocal leukoencephalopathy 
pRb 
 
retinoblastoma protein 
PRR 
 
pattern recognition receptors 
PYD 
 
pyrin domain 
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PyVAN 
 
polyomavirus associated nephropathy 
PyVHC 
 
polyomavirus associated hemorrhagic cystitis 
PyVs 
 
polyomaviruses 
RBC 
 
red blood cells 
RFC 
 
replication factor C 
RIG-I 
 
retinoic acid-inducible gene I  
RLR(s) 
 
(RIG-I)-like receptor(s)  
RNA 
 
ribonucleic acid 
RPA 
 
replication protein A 
rr-NCCR 
 
rearranged non-coding control region 
SOT  
 
solid organ transplantation 
sTag 
 
small T antigen 
STLPyV 
 
Saint Louis polyomavirus 
SV40 
 
simian vacuolating virus 40 
TAP1/2 
 
transporters associated with antigen processing-1/2 
TCR 
 
T cell receptor 
TLR(s) 
 
Toll-like receptor(s) 
TsPyV 
 
Trichodysplasia spinulosa polyomavirus 
VLP(s) 
 
virus-like particle(s) 
VP1 
 
major capsid protein 1 
VP2 
 
minor capsid protein 2 
VP3 
 
minor capsid protein 3 
VSV 
 
vesicular stomatitis virus 
wt 
 
wild type 
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2 Summary 
JC polyomavirus (JCPyV) and BK polyomavirus (BKPyV) were identified as the first of now 
more than 12 human polyomaviruses (HPyVs). The average JCPyV and BKPyV seroprevalence 
rates in adults are 70% and 90%, respectively. After asymptomatic infection both viruses 
persist in the renourinary tract. In fact, asymptomatic viruria is detectable in one-third of 
general population. However, in immunocompromised patients, JCPyV and BKPyV 
replication may progress to significant diseases. Hence, JCPyV can cause progressive 
multifocal leukoencephalopathy (PML) in patients with HIV-AIDS, malignancies or 
autoimmune diseases under immunosuppressive treatment. BKPyV can be a cause of 
polyomavirus-associated nephropathy (PyVAN) in kidney transplant recipients or 
hemorrhagic cystitis (PyVHC) after allogeneic hematopoietic stem cell transplantation. Due 
to more frequent application of immunosuppression, the risk of developing these diseases 
has increased in the last few decades. The risk of PML development is estimated to be 100-
fold higher for JCPyV-seropositive patients in comparison to JCPyV-seronegatives. Most 
cases of PyVAN and PyVHC have been tested positive for BKPyV at the moment of disease 
diagnosis. Unfortunately, there is no specific antiviral therapy against any of these HPyV 
diseases. Thus, current strategies to avert PyVAN or PyVHC aim at identifying patients with 
BKPyV viremia and reducing immunosuppression. Similar strategies for PML have not been 
effective, since JCPyV viremia is usually not detected prior to or at the diagnosis of disease. 
The fate of BKPyV and JCPyV virus-like particles (VLPs) was examined in an animal model 
corresponding to primary viremia in non-immune host. Radioactively labeled VLPs were 
used to assess blood decay, organ, and hepatocellular distribution of ligand, and non-labeled 
VLPs to examine cellular uptake by immunohisto- and cytochemistry. Rapid distribution of 
both BKPyV and JCPyV VLPs to the liver was observed, with lesser uptake in kidney and 
spleen. Liver uptake was predominantly observed in LSECs. Blood half-life and tissue 
distribution of both wild-type JCPyV VLPs and two mutant JCPyV VLPs (L55F and S269F), 
lacking sialic acid binding affinity, were similar, indicating involvement of non-sialic acid 
receptors in cellular uptake. We concluded that LSECs very effectively cleared a large 
fraction of blood-borne BKPyV and JCPyV VLPs, indicating a central role of these cells in early 
removal of polyomavirus from the circulation. Moreover, we observed that a subpopulation 
of endothelial cells in kidney, the main organ of polyomavirus persistence, showed selective 
and rapid uptake of VLPs, suggesting a role in viremic organ tropism (Simon-Santamaria et 
al., p. 54). 
5 
 
Giving the increasing clinical need to reliably determine JCPyV and BKPyV IgG levels in 
patients at risk, we first reviewed and optimized serological tools for JCPyV and BKPyV IgG 
detection including virus-like particle (VLP)-based ELISA. We demonstrated that although no 
statistically significant differences in intraassay and interassay variability were revealed for 
JCPyV serology of 400-fold diluted sera from healthy donors, qualitative differences were 
seen in the identification of the individual JCPyV serostatus. The cause of discordance for 
approximately 10% of sera resulted from a low IgG activity close to the cutoff of the assay. 
Therefore we standardized the ELISA using reference serum for normalization. Moreover, 
we developed a preadsorption assay with cutoff of 35% reduction of the JCPyV IgG activity 
after preincubation with JCPyV VLPs. Importantly, we excluded BKPyV antibody cross-
reactivity by testing JCPyV IgG positive sera in preadsorption assay using BKPyV VLPs. In 
conclusion, we showed that VLP-based ELISA with normalization can serve as a reliable tool 
for JCPyV IgG serology. Additionally, the preadsorption assay can help with unequivocal 
determination of JCPyV serostatus for samples with low IgG levels. (Kardas et al., p. 72). 
We also normalized this VLP-based ELISA for BKPyV IgG detection and showed that for 
seroepidemiology studies, normalized JCPyV and BKPyV IgG ELISA at 1:200 serum dilution 
provides optimal sensitivity and specificity with the lowest false-positive and false-negative 
rate. However, for individual risk assessment, 100-, 200-, and 400-fold dilutions combined 
with preadsorption for low-reactive sera might be the most appropriate (Kardas et al., p. 82).  
This improved ELISA was used to investigate JCPyV and BKPyV specific antibody levels in 
several clinical studies: (1) one case of PML patient where positive JCPyV IgG status was 
compatible with other PML-indicating symptoms (Kurmann et al., p. 90); (2) one case of 
PyVAN caused by JCPyV rather than BKPyV, as confirmed by JCPyV IgG/IgM positive and 
BKPyV IgG/IgM negative results (Lautenschlager et al., 99); (3) one case of PyVHC patient 
after allogeneic hematopoietic stem cell transplantation where increasing BKPyV IgG 
activities were in line with progression of BKPyV viremia (Koskenvuo et al., p. 106). Further, 
by serological testing of 122 immunocompetent and 63 immunocompromised patients we 
demonstrated that the BKPyV IgG level is age-dependent, with the highest values between 
20 and 30 years (Schmidt et al., p. 119).  
In another study we compared serological outcomes of ELISA utilizing two different antigens 
in terms of prognostic value in prostate cancer development. To accomplish this we utilized 
improved ELISA for BKPyV IgG activity to both BKPyV VLPs and BKPyV LTag. Testing of 226 
patients undergoing radical prostatectomy for primary prostate cancer revealed that BKPyV 
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VP1 serostatus, in contrast to BKPyV LTag, has no prognostic value in prostate cancer 
progression (Keller et al., p. 125). 
In conclusion, we provided a new input into knowledge about tropism and clearance of 
polyomaviruses from blood. Moreover, we established a reliable and sensitive VLP-based 
assay for specific detection of JCPyV and BKPyV IgG and IgM. Serostatus based on ELISA 
results was compatible with other symptoms of BKPyV- and JCPyV-related diseases. 
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3 Introduction 
 
3.1 Human Polyomaviruses (HPyVs) 
 
The family Polyomaviridae comprises of three genera: two mammalian genera designated 
Orthopolyomavirus and Wukipolyomavirus, and the avian genus Avipolyomavirus (Fig. 1) (1, 
2). JC and BK polyomaviruses (JCPyV and BKPyV), closely related to most intensely studied 
animal virus simian virus 40 (SV40), were the first PyVs to be discovered in humans (3-5). 
More recently, increased interest in innovative screening methods have led to discovery of 
ten previously unknown human polyomaviruses (HPyVs), including Merkel cell polyomavirus 
(MCPyV). This virus can be found in tumor cells of Merkel cell carcinoma, a skin cancer 
affecting mostly immunocompromised individuals (6). Another HPyV Trichodysplasia 
spinulosa polyomavirus (TsPyV) was identified in a rare skin disease with a typical striking 
development of keratin spicules originating from unusual hair follicles in 
immunocompromised patients (7). Further, human polyomavirus 6 (HPyV6) and 7 (HPyV7) 
were first detected on the skin of healthy individuals. Human polyomavirus 9 (HPyV9) was 
found in a serum sample from kidney transplant recipient and human polyomavirus 10 
(HPyV10) was identified in papillomavirus-induced anal condylomata (8-10). Saint Louis 
polyomavirus (STLPyV), which is closely related to HPyV10, was identified in stool samples 
from both healthy and diarrhea-inflicted children, whereas human polyomavirus 12 
(HPyV12) was detected in liver tissue (11). New Jersey polyomavirus (NJPyV) is a novel 
polyomavirus that may have been discovered recently in a pancreatic transplant recipient 
with retinal blindness and vascuolitic myopathy showing tropism for vascular endothelial 
cells (12). According to the International Committee on Taxonomy of Viruses JCPyV, BKPyV, 
MCPyV, TsPyV, HPyV9/10/12, STLPyV, NJPyV belong to Orthopolyomavirus genus, whereas 
HPyV6/7 and another two HPyV, Karolinska Institute polyomavirus (KIPyV) and Washington 
University polyomavirus (WUPyV) identified in airway samples from patients with 
respiratory disease, are part of Wukipolyomavirus genus (Fig. 1) (2, 13). 
 
8 
 
 
Figure 1. Phylogenetic tree of Polyomaviridae family [from (2)] 
 
HPyVs infect a large part of the general population with different age-dependent patterns 
(14-16). MCPyV seroprevalence increases drastically in childhood and remains constant 
through life (17). For JCPyV, seroprevalence increases slowly during childhood and continues 
increasing during life (15).  On the other hand the seroprevalence of BKPyV increases during 
childhood but starts declining at the age of 40 (15). Those seroprevalence differences 
indicate that HPyVs are transmitted independently of one another and carry various risks of 
exposure and reexposure throughout the entire life (18). 
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3.1.1 JC and BK Polyomaviruses  
 
3.1.1.1 Viral Background 
 
3.1.1.1.1 Virion and Genome Organization 
 
The outer surface of every polyomavirus is a naked protein capsid composed entirely of a 
single virus-encoded protein called major capsid protein 1 (VP1). The virion contains a total 
of 72 pentameric VP1 capsomers arranged in T=7 icosahedral structure of approximately 40-
45 nm in diameter. Inside the capsid, one molecule of either minor capsid protein 2 (VP2) or 
minor capsid protein 3 (VP3) is attached to each VP1 pentamer (Fig. 2). The N-terminus of 
VP1 is responsible for the interaction with other VP1 proteins in the same pentamer, while 
the C-terminus reaches out into the neighboring pentamer to interact with VP1, thereby 
stabilizing the capsid. VP2 and VP3 interact with the VP1 molecule through hydrophobic 
interactions (19). It is believed that both VP2 and VP3 are important for packing JC 
polyomavirus (JCPyV) and BK polyomavirus (BKPyV) genomes into virions as well as for 
uncoating and delivery of viral genome to the host cell nucleus (20, 21). 
 
 
Figure 2. JCPyV and BKPyV structure 
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The HPyV virion encapsidates a circular double-stranded DNA of about 5100-5300 base pairs 
(bp), organized around histones in a core-like structure. The BKPyV genome shares 75% of 
overall homology with JCPyV (22). Similar to other PyVs, the genome of both viruses can be 
divided into three parts: the non-coding control region (NCCR), the early viral gene region 
(EVGR) and the late viral gene region (LVGR) (Fig. 3).  
 
 
Figure 3. JCPyV and BKPyV genome organization [adapted from (2)] 
 
The NCCR covers about 400 bp and corresponds to the nucleosome-free area between early 
and late region (19). It contains origin of viral replication ori, TATA- and TATA-like sequences 
for both early and late viral gene transcription, many DNA- and transcription factor- binding 
sites, promoter and enhancer elements as well as binding sites for large T-antigen (LTag). 
The EVGR is about 2400 bp in size close to the left side of the origin of replication ori and 
encodes small T-antigen (sTag), LTag, and the truncated LTag (TruncTag). TruncTags have a 
common N-terminal part but differ in C-terminal part, due to alternative splicing of one pre-
mRNA. Polyomaviruses do not encode viral DNA polymerases, therefore the genome 
replication relies on host-cell enzymes. However, LTag contains DNA unwinding/helicase 
activity and therefore regulates DNA replication as well as LVGR expression. All the 
transcription processes of the virus are completely dependent on host-cell transcription 
factors (23). Thus, cell activation by growth factors and other signals may initiate and 
facilitate these events. 
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The LVGR covers about 2300 bp more distant to the origin of replication ori and contains the 
open reading frames (ORFs) of the structural proteins VP1, VP2 and VP3. Additionally, the 
JCPyV LVGR encodes a small protein called Agno, found only in BKPyV and simian 
vacuolating virus 40 (SV40). Although, there are many speculations about its properties, the 
function of Agno remains unknown (24, 25). 
 
3.1.1.1.2 Genotypes 
 
3.1.1.1.2.1 JCPyV Genotypes and Subtypes 
 
Sequencing of the JCPyV genome revealed at least seven major genotypes and numerous 
subtypes (26). All genotypes were detected in different geographic areas of the world (Fig. 
4). Types 1 and 4 are the most common genotypes in Europeans, Types 2 and 7 are more 
frequent among Asians, and Types 3 and 6 in Africans. For each of the genotype one to five 
subtypes have been identified.  
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Figure 4. Phylogenetic reconstruction of JCPyV genome development  
[modified from (27) and (28)] 
 
3.1.1.1.2.2 BKPyV Genotypes and Subtypes 
 
Based on nucleotide sequence analysis of all known genome-full-length isolates, BKPyV can 
be categorized into four major genotypes, namely I, II, III, and IV (29). Neutralization 
experiments show that all BKPyV genotypes are fully distinct serotypes (30, 31). Due to 
expansion of BKPyV diversity and arising difficulties in assigning viral strains to existing 
subtypes, additional subgroups within the four major subtypes have been appointed (32-34). 
Thus, subtype I is the most frequent and has a worldwide distribution, subtype IV is the 
second most frequent and might be more frequently detected in Eastern Asia. Although 
subtypes II and III are found worldwide, their frequencies are low (35, 36). Additionally, 
according to the phylogenic investigations subtype I can be divided into 4 subgroups 
including subgroups Ia, Ib1, Ib2 and Ic, with broad geographical distribution. Subtype IV is 
divided into six subgroups in phylogenic studies including IVa1, IVa2, IVb1, IVb2, IVc1 and 
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IVc2 (6, 7) (Fig. 5). It might be that different BKPyV genotypes have different cellular 
tropisms and pathogenic potentials in vivo (30).  
 
 
Figure 5. Phylogenetic reconstruction of BKPyV genomes development 
[modified from (34)] 
3.1.1.1.3 Viral Life Cycle 
 
JCPyV attaches to the terminal α2,6-linked sialic acid-bearing structures (mostly 
glycoproteins and glycolipids) on the host cell surface (Fig. 6). Additional or alternative 
receptor might also be involved, such as the 5-hydroxy-tryptamine-2A serotonin receptor 
(5HT2AR) (37). Terminal α2,6-linked sialic acids which could bind virions have been identified 
on oligodendrocytes and astrocytes, on B-lymphocytes in tonsils and spleen, and in kidney 
and lung tissue, which stays in line with results from studies on the tissue distribution of 
JCPyV DNA (38-41). It is suggested that after attachment of JCPyV to 5HT2AR and terminal 
α2,6-linked sialic acid, internalization of the virus mediated via clathrin-coated pits takes 
place. Further steps include caveolin-1 and pH-dependent transport along the cellular 
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cytoskeleton to the endoplasmic reticulum (ER) (42-44). The caveolae are then transported 
to the caveosome, a vacuolar structure with a neutral pH, functioning as a sorting 
compartment. 
BKPyV infection is mediated by binding of major capsid protein VP1 to the α2,3-linked sialic 
acid structures including GD1b and GT1b gangliosides, responsible for mediating cellular 
recognition and cell-to-cell interaction (19, 42, 45, 46). Both GD1b and GT1b are present on 
kidney and urinary tract cells making them the main sites of the viral infection and 
replication (47). After binding to the receptor on the cell surface, the virus is internalized via 
caveolae-mediated endocytosis (48, 49) (Fig. 6). Caveolin-1 and cholesterol-enriched lipid 
rafts mediate plasma membrane invagination and vesicle generation (50-52).  
The following steps of life cycle are similar for both JCPyV and BKPyV (49, 53). After 
transport to the ER, partial uncoating of the virion takes place. Disulfide isomerases available 
in ER induce conformational changes in the VP1 structure of both viruses, facilitating capsid 
disassembly prior to its entry into the nucleus. For BKPyV, it has been shown that Derlin-1, a 
member of the ER-associated degradation (ERAD) pathway, works as a retro-translocation 
channel to transport the virus to the cytosol through the interaction with VP1, prior to entry 
into nucleus (49, 54). It has been proposed, that BKPyV might use the proteasome to enable 
a more efficient disassembly of the capsid in the cytosol (49, 55, 56).  
 
 
Figure 6. JCPyV and BKPyV life cycle 
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The detailed steps of the viral entry into the nucleus are not well defined. Nevertheless, due 
to size of the virion (40-45 nm), its transport might be limited, as the nuclear pore complex 
allows to pass only particles up to 39 nm (57). Moreover, a nuclear localization signal (NLS) 
located at the N-terminus of VP2 and VP3 has to be exposed to enable efficient transport 
into the nucleus. Therefore, the virion has to be partially disassembled in the ER for the NLS 
recognition and the passage through the nuclear pore.  
After the entry of a viral DNA into the nucleus, decision on replication or latency must occur. 
This decision is well defined and the latency depends on host cell fitness, its differentiation 
potential and the immune status of the host. 
In case of the EVGR, expression begins from the left TATA box promoter and progresses in 
one direction half around the circular genome. Although mRNA of LTag and sTag are 
translated in the cytosol (58), LTag is immediately transported to the nucleus, whereas sTag 
stays in the cytoplasm. sTag interacts with retinoblastoma proteins (pRb) enabling the 
release of members of the E2F family of transcription factors from their Rb partners to 
promote cell cycle progression (59). sTag also inhibits phosphatase 2A (PP2A). However, a 
direct role of sTag in promoting viral replication has not been defined. LTag on the other 
hand is necessary for replication of the viral genome as a result of its DNA binding and 
helicase activities (60). LTag is thought to promote viral replication directly by binding to 
viral DNA and viral proteins, as well as indirectly by interaction with key regulatory proteins 
of the host cell. Taking SV40, six copies of LTag assemble into two hexameric structures at 
the NCCR and initiate bidirectional melting of viral genome (61). Hexameric LTag also 
recruits host cell polymerase and DNA-binding proteins to the replication fork in order to 
facilitate viral DNA replication. LTag also conveys a negative expression feedback of its own 
transcription by interaction with binding sites in NCCR, thereby initiating expression of LVGR 
proteins (2). Similarly to sTag, LTag ensures activity of the cell through binding to the pRb 
and inhibition of its function. In an active state, pRbs cause a cell cycle arrest through 
formation of a complex with histone deacetylases (HDACs) and the transcription factor E2F 
(19, 62). After binding of pRb by LTag, E2F is released, thereby inducing the transcription of 
E2F-dependent genes encoding cyclins, checkpoint regulators. The expression of proteins 
promoting DNA repair and replication leads to a cell cycle progression accompanied by viral 
replication (19, 62). LTag also prevents the host cell from p53-mediated apoptosis which 
would be caused by accumulating amplified DNA fragments and metabolic exhaustion (60, 
63).  
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The LVGR expression is initiated by interaction of LTag with cellular transcription factors, 
including DNA polymerase α, topoisomerases and replication protein A (RPA), and their 
binding to the NCCR (64, 65). After transcription of LCGR, its common mRNA is alternatively 
spliced and translated into proteins. Thereafter, capsid proteins undergo posttranslational 
modifications including myristoylation of the N-terminus of VP2 and VP3 as well as 
formation of disulfide bridges between VP1 proteins, which prevents the single pentamers 
from dissociation (19). After translation of capsid proteins, they are transported from cytosol 
into the nucleus, whose mechanism is still not revealed. The assembly of the virions with 
viral encapsidated viral DNA then takes place, leading to nuclear inclusions and enlargement 
and eventual lysis of the cell (19, 66).  
 
3.1.2 Clinical Implications 
 
3.1.2.1 Epidemiology of JCPyV Infection 
 
Numerous reports on JCPyV seroprevalence indicate presence of anti-JCPyV antibodies in 30 
to 70% of healthy individuals (2, 14-16). Diverse rates among different age groups indicate 
that JCPyV exposure occurs at least in two life periods: in childhood with seroprevalence 
reaching around 25% in early adolescence, followed by the second phase in adulthood with 
up to 70% JCPyV seroprevalence among old people (14-16, 67). There is also a regional 
variation of JCPyV seropositivity ranging from 47% in Norway to 68% in Turkey (68). JCPyV 
persists in the renourinary tract and viral replication is detected as asymptomatic viruria in 
approximately 30% of immunocompetent JCPyV seropositive individuals (15). Since 
seroprevalence of around 80% has been reported for BKPyV, it can be assumed that both 
viruses are transmitted independently and probably through various routes. Exposure and 
re-exposure to JCPyV is associated with a seroconversion of 1 to 2% per year, which has 
been not observed for BKPyV (15, 69).  
 
3.1.2.2 JCPyV-Associated Diseases 
 
In immunocompetent individuals JCPyV infection is not definite and may be subclinical or 
unspecific. The major JCPyV-associated diseases occur in the context of immunological 
impairment of an efficient control of viral replication in the central nervous system (CNS) 
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and kidney and possibly in other sites, e.g. colon (2).  The interest in progressive multifocal 
leukoencephalopathy (PML) has increased due to a widespread use of different 
immunosuppressive drugs. Moreover, cases of JCPyV-associated nephropathy in kidney 
transplant recipients have appeared as well as other pathologies including some forms of 
cancer (Table 1) (70). 
 
3.1.2.2.1 Progressive Multifocal Leukoencephalopathy (PML) 
 
JCPyV is the causative agent of PML, a rare and frequently fatal brain disease preferentially 
affecting the white brain matter and is caused by cytopathic replication of the virus in 
myelin-producing oligodendrocytes (2, 71-74). The pathology of the affected brain tissues 
demonstrates oligodendroglia-like cells with viral inclusions in their enlarged nuclei, one of 
the diagnostic hallmarks of this disease (68, 71, 73, 74). The lack of an animal model and the 
need to investigate PML only in humans made the understanding of the disease very difficult. 
However, it has changed in the last 50 years. Due to an increased rate of PML in HIV-AIDS 
patients and more common use of new biologic therapies of multiple sclerosis (MS) and 
autoimmune conditions (e.g. rheumatoid arthritis), there are more opportunities to study 
this disease (75). Moreover, highly sensitive molecular techniques allow nowadays detecting 
even very low level of virus. Additionally, estimation of PML risk for patients undergoing 
newer therapies for cancer, solid-organ and hematologic transplantation, multiple sclerosis, 
and other autoimmune diseases has increased the general knowledge in this field (76-81).  
 
3.1.2.2.1.1 Risk of Developing PML Among People with Different Cause of 
Immunodeficiency 
 
PML affects a small fraction of immunocompromised patients, including those with HIV-AIDS 
and transplant recipients on immunosuppressive drug therapies. Nowadays, HIV infection is 
still the most frequent setting for PML, 80% of the cases, followed by hematologic 
malignancies (approximately 8%), solid cancers (around 3%), organ transplantation, and 
autoimmune diseases treated with immunomodulators (82). Due to various 
immunosuppressants being used, the risk of PML development varies between different 
groups of patients. The incidence of PML in the general population was estimated as 0.3 per 
100 000 persons years compared to 1.0 for patients with rheumatoid arthritis (83, 84). The 
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incidence in HIV-AIDS individuals is estimated as 2.4 cases per 1 000 patients years (reported 
for Switzerland and Denmark) (85, 86). Among patients after solid organ transplantation 
(heart or lung) the PML incidence have been observed for 1.24 patients out of 1 000 (76).  In 
patients with rheumatoid arthritis treated with rituximab, a depleting monoclonal antibody 
targeting CD20+ B cells, the prevalence of PML was estimated as 1 in 25 000 patients (87).  
For multiple sclerosis patients approximate risk of PML development depends on several 
factors including JCPyV serostatus, prior therapy of multiple sclerosis with 
immunosuppressive drugs and duration of natalizumab treatment (Fig. 7).  
 
 
Figure 7. Approximate incidence of PML among multiple sclerosis patients 
stratified according to different risk factors 
 
For patients receiving natalizumab for at least 2 months, 2.13 PML cases per 1 000 patients 
were reported (2, 88). Taking the risk of PML stratified according to three risk factors, the 
incidence of PML is the lowest among the patients who are negative for anti–JCPyV 
antibodies, with the estimation of less than 0.09 cases per 1 000 patients. Patients who are 
positive for anti–JCPyV antibodies, had taken immunosuppressants before the initiation of 
natalizumab therapy, and have received 25 to 48 months of natalizumab treatment have the 
highest estimated risk of 11.1 cases per 1 000 patients (68). 
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3.1.2.2.1.2 Various Hypotheses Concerning PML Pathogenesis 
 
 
The detailed steps of PML development remain unknown due to the lack of definitive human 
data (73). The time between onset of JCPyV replication in the brain and accumulation of 
cytopathic damages leading to clinical and radiological abnormalities is still unclear. 
Moreover, the relevant sites of JCPyV latency, including compartments where the virus 
acquires the most pathogenomic NCCR rearrangements (rr-NCCR) and VP1 capsid protein 
mutations, are not defined (2). However, it is postulated that JCPyV reaches CNS during 
primary viremia where its reactivation is locally censored by specific T-cell effectors. The 
decrease of T-cells function in the CNS permits local replication of JCPyV and cytopathic 
damage progressing to PML. Another theory presents lymphocytes, hematopoietic 
progenitor cells and other cells of the body as a site of JCPyV persistence, where in case of 
decreased activity of JCPyV-specific T-cells the virus can reactivate and occult secondary 
viremia resulting in colonization of susceptible cells in CNS and their eventual cytopathic 
damage. It has been hypothesized that the virus could persist in other cells of besides the 
kidney (lymphocytes or bone marrow progenitor cells) and reach CNS via infected 
lymphocytes migrating to the CNS. The entry of the virus into nervous system would result in 
colonization, local replication and eventual cytopathic damage of CNS cells. The virus 
reactivation hypothesis is supported by the fact that practically all PML patients are JCPyV 
seropositive at the time of PML diagnosis, although the serology testing was performed 
exclusively on HIV-AIDS or MS patients (69, 71, 88-90). 
 
3.1.2.2.1.3 Unique JCPyV Non-Coding Control Region (NCCR) Rearrangements 
 
The archetype JCPyV NCCR has been arbitrary divided into 6 blocks, designated from A to F 
(Fig. 8). Block A covers 36, B - 23, C - 55, D - 66, E - 18 and F - 69 base pairs. The highly 
variable rearrangements in JCPyV NCCR (rr-NCCR) can affect any of the blocks and can 
comprise of duplications (partial, multiple or tandem repeats) or deletions of archetype 
NCCR (at-NCCR) sequence or combination of both (91-93). Some of the NCCR 
rearrangements are unique for PML cases, suggesting their role in the disease pathogenesis. 
PCR amplification and direct sequencing of rr-NCCR sequences allowed the identification of 
some typical rearrangement patterns. The rearrangements in rr-NCCR sequences found in 
PML cases were observed in an ori-distal part of the NCCR close to LVGR and D-block of 
20 
 
NCCR, affecting a part or the entire D-block, whereas duplications occurred in ori-proximal 
part of the NCCR close to EVGR TATA-box as well as in C-block alone or in combination with 
mutations in blocks A and B. Less frequent partial deletions have been observed in blocks E 
and F (92, 94, 95). Sequence analysis of NCCRs from single-sampling site from the same PML 
patient indicates the presence of many different rr-NCCR sequences with a common 
signature but with one dominant rr-NCCR sequence (96). The major JCPyV quasispecies can 
change within 2 days in CSF, retaining nevertheless a rearrangement signature. The NCCR 
rearrangements might appear due to uncontrolled dynamic replication of JCPyV in the brain. 
Errors occurring during viral DNA replication result in generation of quasispecies of JCPyV 
with rr-NCCR with varied replication fitness (92).  
 
 
Figure 8. JCPyV archetype NCCR architecture 
 
However, it cannot be excluded that independent replication generates in parallel new NCCR 
rearrangements. Despite the high variety of NCCR rearrangements, the majority of JCPyV 
quasispecies with rr-NCCR invariably show increased EVGR expression in comparison to 
JCPyV with at-NCCR (92).  
  
3.1.2.2.1.4 Major Capsid Protein (VP1) Mutations Characteristic for PML Patients 
 
Analysis of JCPyV VP1 sequences reveals that a small number of mutations can be found 
exclusively in cerebrospinal fluid (CSF) or brain of PML patients. In fact, between 80 and 90% 
of viral isolates from PML patients exhibit mutations in one or more of the VP1 and these 
mutations have never been found in JCPyV isolates from individuals without PML (97). These 
substitutions affect amino acids located at or close to binding sites for sialic acid structures, 
which enables viral interactions with cellular receptors and hence viral infectivity (98). The 
most frequent changes occur in amino acids 269 and 55 (L55F and S269F) (Fig. 9) (99, 100).  
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Figure 9. Frequency of JCPyV VP1 mutations among 37 PML patients [from (99)] 
 
While wild-type JCPyV causes agglutination of red blood cells (RBC) (due to JCPyV binding 
activity to sialic acid structures present on RBC), the virus with 55F, 267F, 269F or 269Y 
mutation is no longer able to achieve this (99). For some of the mutants, e.g. 60E, 265D and 
271H, hemagglutination is still possible but at much lower level. Those changes in 
hemagglutination ability suggest that these mutations may influence the cell tropism of 
JCPyV in human by abrogating the ability to bind to sialylated molecules on a variety of 
peripheral cell types, but retain the ability to bind CNS glial cells (99). It is not well defined 
where the mutagenesis of JCPyV VP1 takes place. Nevertheless, approximately 10% of PML 
patients carrying the virus without VP1 mutations is still consistent with the hypothesis that 
the mutations occur prior to viral entry into the CNS (99). 
 
3.1.2.2.1.5 Diagnosis and Clinical Presentation of PML 
 
The diagnosis of PML can be viewed as a loss of myelin-producing oligodendrocytes which 
leads to asymmetric and focal lesions in the initial stages of the disease, followed by a 
dramatic subcortical expansion, confluence and even contralateral spread along the corpus 
callosum (73). Magnetic resonance imaging (MRI) is the key non-invasive diagnostic method 
for PML diagnosis (accompanied by clinical symptoms). Typically the lesions are located in 
the subcortical white matter with a sharp border towards the gray matter and diffuse border 
towards the white matter (Fig. 10).  
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Figure 10. Cerebral PML lesions (a, c) of an HIV-negative patient without IRIS  
and (b, d) an HIV-positive patient with IRIS [from (73)] 
 
The diagnosis of histologically confirmed PML requires demyelination in the white matter of 
the brain, compatible cytopathic alterations and specific JCPyV involvement, proven with 
immunohistochemistry for virus proteins (LTag or VP1) or DNA detection by in situ 
hybridization. Detection of JCPyV DNA in CSF is usually accepted as probable PML, called as 
well virologically- or laboratory-confirmed PML (2, 101, 102).  
Based on observations of case series from different PML eras (pre-AIDS era, AIDS-associated 
PML and natalizumab-related PML), the clinical presentation of PML is variable and reflects 
severity and location of the lesions. The general symptoms might include cognitive and 
behavioral abnormalities, visual deficits, motor weakness, gait abnormalities, incoordination, 
sensory loss and headaches (68). Epilepsy, although rare in the initial clinical presentation of 
PML in HIV-AIDS, can be frequently observed among patients with PML lesions in more 
cortical location (103) as well as in patients with radiological signs of inflammation due to 
local immune responses (2). 
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3.1.2.2.1.6 PML Treatment Strategies 
 
There is currently no specific antiviral therapy to PML and the treatment aims at regaining 
control of immune system over JCPyV replication. In transplant recipients, this approach 
requires reduction of immunosuppression, which is limited by increased risk of organ 
dysfunction or even graft rejection. For kidney transplant recipients, a return of 
hemodialysis or discontinuation of immunosuppressive treatment may be indicated for a 
successful outcome (104). For other SOT patients, the reduction of immunosuppression 
might be not feasible to allow for timely recovery of immune control over JCPyV replication. 
Reduction or discontinuation of immunosuppression in HSCT case could lead to a worsening 
of the graft-versus-host disease. For HIV-AIDS patients with PML, the combination 
antiretroviral therapy (cART) might improve the overall outcome. Unfortunately, still 
approximately half of the HIV-patients develop the disease or suffer from significant 
neurological impairment. In case of MS patients undergoing natalizumab treatment, 
immune reconstitution can be successful but sometimes can also lead to significant side 
effects, e.g. immune reconstitution inflammatory syndrome (IRIS). In high-risk patients with 
PML-IRIS, the use of intravenous immunoglobulins may be beneficial due to their 
immunomodulatory activity dempening IRIS (105). Also, adoptive transfer of JCPyV-specific 
T-cells has been reported for a child after allogeneic HSCT (106). This immunologic 
treatment was well tolerated and no recurrence of PML was noted. More attention has been 
also paid to the antivirals cytarabine and cidofovir and uptake blockers mirtazapine, 
chlorpromazine, and mefloquine alone or in combination, with varying success, typically in 
uncontrolled case studies (107-113). 
 
3.1.2.2.2 Other JCPyV-Associated Diseases 
 
JCPyV can also cause other diseases including JCPyV-mediated granule cell neuronopathy 
caused by replication of the virus in granule cell neurons of the cerebellum (114, 115). The 
disease is associated with VP1 C-terminal JCPyV mutations, approximately 10 bp deletions 
resulting in frame shift and a total change of the C-terminal amino acid sequence of the 
protein (116, 117). Clinical symptoms include a cerebellar syndrome with ataxia and 
progressive cerebellar atrophy without involvement of the white matter (114). The JCPyV 
can be detected in CSF. The lesions frequently coexist with PML in the white matter of the 
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cerebellum and cerebrum. The proposed treatment is based on regaining immune control 
over JCPyV replication. 
JCPyV-associated encephalopathy is another disease caused by cytopathic JCPyV replication 
in the gray matter, this time targeting the cortical pyramidal neurons (118). It is 
characterized by lesions expanding from the gray matter to subcortical areas and by 
presence of the virus in the CSF of the patient.     
JCPyV-associated meningitis and encephalitis have been discovered in patients with typical 
symptoms of meningeal inflammation, including neck stiffness, headache, fever and JCPyV 
present in CSF (119, 120). However, no clinical sign of neurologic deficits characteristic for 
PML has been found. The diagnosis is based on clinical symptoms of meningitis and presence 
of JCPyV in the CSF. 
 
 Classic PML PML-IRIS 
JCPyV granule cell 
neuronopathy 
JCPyV encephalopathy JCPyV meningitis 
Onset Subacute Immune recovery Chronic Subacute Acute 
Radiological 
findings (MRI) 
Asymmetric, well 
demarcated, non-
enhancing subcortical 
white matter lesions, 
hyperintense in T2 and 
FLAIR, hyperintense in 
T1 
Contrast enhancement 
and mass effect 
Cerebellar atrophy Cortical lesions 
No defined lesions, 
ventricular dilatation 
Neurological 
symptoms 
Based on location 
Based on location and 
inflammation 
Cerebellar syndrome Encephalopathy 
Headache, stiff neck, 
fever 
Diagnosis 
JCPyV detection in the 
CSF, brain biopsy, 
radiographical findings 
and symptoms 
JCPyV in the CSF, brain 
biopsy, radiographical 
findings and 
symptoms 
Cerebellar biopsy, 
JCPyV in the CSF, 
radiographical findings 
and symptoms 
Brain biopsy, JCPyV PCR 
in the CSF, radiographical  
findings and symptoms 
JCPyV in the CSF and 
exclusion of other 
viruses 
Histology 
Demyelinating lesions 
often at grey/white 
junction, JCPyV detected 
in enlarged 
oligodendrocytes, 
bizarre astrocytes 
Demyelination similar 
to classic PML, with 
addition of 
inflammatory 
infiltrates 
Lytic infection of 
granule cell neurons in 
the cerebellum by 
JCPyV 
Lytic infection of cortical 
pyramidal neurons and 
cortical astrocytes by 
JCPyV 
 
Treatment 
cART for HIV-positive 
patients, discontinue or 
decrease 
immunosuppression for 
HIV-negative patients, 
plasma exchange for 
natalizumab-treated 
patients 
Similar to PML, 
consider steroids in 
cases with notable 
neurological 
worsening or signs of 
impending brain 
herniation 
Similar to classic PML Similar to classic PML Similar to classic PML 
 
Table 1. Clinical presentations of JCPyV-related neurological diseases [from (121)] 
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Nephropathy due to JCPyV (JCPyVAN) is a rare complication affecting approximately 1% of 
kidney transplant recipients causing severe graft dysfunction and its eventual loss (122, 123). 
This complication leads to the decline of the renal allograft function, very high JCPyV load 
and decoy cells shedding in urine. Morphologically, JCPyVAN and BKPyVAN are 
indistinguishable. Blood or plasma test could be unreliable due to frequently very low or 
even undetectable amount of JCPyV DNA (124). JCPyVAN is usually confirmed with 
immunohistochemical detection of LTag in renal tubular epithelial cells by cross-reactive 
SV40 antibodies. The pathology of JCPyVAN occurs without NCCR rearrangements (125). 
JCPyVAN can be treated by reducing immunosuppression leading to stabilization of allograft 
function during follow-up and to clearance of the virus (122).  
The transforming potential of JCPyV makes it interesting in terms of human malignancies. 
Numerous human malignancies have been associated with JCPyV including 
oligodendroglioma, astrocytoma, medulloblastoma, ependymona and glioblastoma (103, 
126-129). 
 
3.1.2.3 Epidemiology of BKPyV Infection 
 
Epidemiological studies revealed that BKPyV infection occurs during early childhood at a 
median age of 4–5 years through the respiratory or oral route (14, 130). After primary 
infection BKPyV persists in the renourinary tract as the principal site (131). It is unknown if 
this is a truly latent infection, with no replication and limited or no viral gene expression, or 
if it is a persistent infection, with low-level viral replication. However, it has been shown that 
spontaneous reactivation of BKPyV and its asymptomatic urinary shedding occurs in up to 
62% of healthy BKPyV-seropositive individuals (130, 132, 133). The overall seroprevalence 
for BKPyV among human population reaches up to 90% (14-16). The number of seropositive 
individuals increases until the age of 40 years and then slightly decreases (14, 16). 
Interestingly, this is in contrast to JCPyV which seroprevalence increases throughout life (14-
16, 29).  
 
3.1.2.4 BKPyV-Associated Diseases 
 
Primary BKPyV infection is not associated with any well-defined clinical symptoms in 
immunocompetent individuals. Reactivation of latent virus could however occur in old age, 
diabetes mellitus, pregnancy, congenital immunodeficiency, HIV-AIDS and most importantly, 
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kidney transplantation. The first sign of reactivation is BKPyV viruria, which has been 
reported in 15-60% of kidney transplant patients (134, 135). This is followed by BKPyV 
viremia and BKPyV-associated nephropathy (BKPyVAN) seen respectively in 5-30% and 1-
10% of kidney transplant patients (134-138). In bone marrow transplant recipients, 
hemorrhagic cystitis is an important clinical syndrome attributed to BKPyV infection, 
particularly after radiation and chemotherapy (139-142). Other diseases caused by BKPyV 
infection include ureteric stenosis and bladder cancer. Diseases affecting regions outside of 
the urogenital tract associated with BKPyV have only rarely been seen in the form of 
myopathy in kidney transplant recipient or disseminated infection in AIDS patients as well as 
single cases of encephalitis and meningoencephalitis (143, 144). 
 
3.1.2.4.1 Polyomavirus-Associated Nephropathy (PyVAN) 
 
It has been reported, that PyVAN affects between 1 and 10% of kidney transplant patients 
during the first two years post-transplantation (135, 145-147). PyVAN rarely affects patients 
other than kidney transplant recipients and so far only few cases of the disease in native 
kidneys of other immunocompromised patients have been reported (148).  
 
3.1.2.4.1.1 PyVAN Pathogenesis 
 
The impairment of immune response allows BKPyV to be reactivated, leading to its 
replication and host cell death. The nephropathy is manifested as damage of tubular 
epithelial cells due to extensive viral replication causing their eventual lysis (136, 149). The 
damage to the tubules can be observed along the whole nephron. However, the proximal 
tubules, the collective duct and the distal tubules are usually the most affected by extensive 
viral replication (150, 151). As a consequence, virus leaks into the bloodstream and 
inflammatory cells infiltrate the interstitium leading to tubular atrophy and interstitial 
fibrosis (152, 153). This impairs the graft function and increases the risk of graft rejection. 
Importantly, the urothelial cells may also play a role in PyVAN. Modeling of BKPyV 
replication in kidney transplant patients with PyVAN suggests that although viral replication 
starts in the renal tubular epithelial cells, BKPyV is later carried to the urothelial cell 
compartment where more than 90% of urine BKPyV loads are generated (154). 
Histopathological data revealing extensively infected urothelial cells in the bladder of 
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patients with PyVAN confirm the suggested model (150). 
 
3.1.2.4.1.2 Diagnosis and Clinical Presentation of PyVAN 
 
The clinical presentation of PyVAN is insidious and allograft function decreases with 
persistent disease indicating progressive involvement of BKPyV replication. Typical signs of 
viral replication can be observed in tubular epithelial cells including enlargement of nuclei 
with smudgy chromatin changes, intranuclear inclusions, rounding, and eventual 
detachment of the cell from tubular walls (146, 151, 155, 156). In further phase of PyVAN 
development, extensive renal involvement is observed with multifocal cytopathic alterations, 
necrosis, accompanied by inflammatory response, and first signs of fibrosis. The 
inflammatory infiltrate contains polymorphonuclear cells, monocytes, and plasmacytoid cells 
in varying distributions (146, 150, 157). Further on, interstitial fibrosis, scarring, and even 
calcifications could occur. The tubuli become flattened and atrophic and sometimes few 
polyomavirus-infected cells are detectable. 
It is strongly recommended to screen kidney transplant patients regularly for early diagnosis 
(158). Screening for PyVAN can be achieved by detection of BKPyV replication in the urine to 
identify patients at risk. Various techniques and urine cytology have been used to identify 
decoy cells or quantitative PCR of urine and/or plasma for detection of high-level BKPyV 
viruria (159). Importantly, plasma PCR has a higher positive predictive value in comparison 
to urine PCR as episodic viruria is quite frequent in this patient group, while viremia is less 
common and usually precedes PyVAN (135). Alternatively, cytological examination of urine 
in search of decoy cells or electron microscopy can be performed (160). Most of the time the 
complete diagnosis of PyVAN requires a histological demonstration of BKPyV replication. 
However, a negative biopsy result cannot exclude PyVAN, due to its focal nature (149, 161). 
 
3.1.2.4.1.3 PyVAN Treatment Strategies 
 
The management of PyVAN is difficult due to the lack of standard protocol and effective 
antiviral drugs. BKPyV infection remains latent with its predisposition to reactivation and 
regaining of patient immune function is needed to eventually control BKPyV replication. The 
most widely used interventions include reduction, change or discontinuation of 
immunosuppression. These approaches are nevertheless connected with a risk of acute graft 
rejection. After decrease of immunosuppression, the serum creatinine value has to be 
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monitored in 1-2 week intervals and the BKPyV viremia in 2-4 week intervals (158). When 
the disease is detected at an early stage, a reduction in the immunosuppression is often 
sufficient to clear BKPyV viremia and stop the progression of disease (162-164). Clearance of 
BKPyV occurs in >85% of BKPyVAN cases, although more advanced stage of PyVAN may 
require more comprehensive intervention (138, 163, 165). In comparison to strategy based 
on reduction in immunosuppression alone, there is no evidence to support the use of any 
other drugs combined with reduction in immunosuppression (166). Nevertheless, cidofovir 
(intravenously administered nucleoside analogue of deoxycytidine monophosphate), 
leflunomide (orally administered drug which indirectly leads to decrease of T- and B-
lymphocytes proliferation), fluroquinolones (synthetic broad spectrum antimicrobial agents 
suggested to interfere with the helicase activity of BKPyV LTag) and intravenous 
immunoglobulins are sometimes used as adjunctive therapies (167-170). 
 
3.1.2.4.2 Polyomavirus-Associated Haemorrhagic Cystitis (PyVHC) 
 
Haemorrhagic cystitis has an incidence of 5 to 15% in allogeneic haematopoietic stem-cell 
transplantation (171-173). Causative factors include urotoxic conditioning procedures and 
total body irradiation as well as viral infections including BKPyV and adenovirus. In terms of 
further therapy, it is important to distinguish BKPyV-associated hemorrhagic cystitis from 
cyclophosphamide-associated HC (174). Although PyVHC usually affects allogeneic HSCT 
patients, single cases have been reported in other immunocompromised patients (130). 
 
3.1.2.4.2.1 PyVHC Pathogenesis 
 
Although the pathogenesis of PyVHC is not well understood, sequence of events has been 
suggested as cause of the disease (150, 175). Those include subclinical damage of bladder 
mucosa by acroleine - a toxic metabolite of cyclophosphamide (used as conditioning 
protocol prior HSCT), immunologically uncontrolled high-level replication of BKPyV resulting 
in uncovering of the damaged bladder mucosa, and inflammation occurring during 
engraftment of the stem cell graft. 
 
 
 
29 
 
3.1.2.4.2.2 Diagnosis and Clinical Presentation of PyVHC 
 
In contrast to PyVAN cases, BKPyV viremia is not consistently seen in patients with 
haemorrhagic cystitis (176). To discriminate PyVHC from haemorrhagic cystitis occurring 
prior to the engraftment due to urotoxic conditioning or total body irradiation, the triad of 
cystitis, hematuria (grade II or more) and high-level BKPyV replication need to be reported. 
Additionally, plasma BKPyV load should be also measured (135, 177, 178). As viral 
determinants of haemorrhagic cystitis, altered nuclear factor 1 (SP1) transcription sites in 
the BKPyV NCCR have been reported (179). Organ determinants may reside in tissue injury 
elicited by conditioning, which may provide an increased number of regenerating cells for 
BKPyV replication. Conditioning for HSCT impairs the BKPyV-specific cellular immune 
surveillance and provides the grounds for extensive BKPyV replication. On engraftment, 
recovering immune cells including polymorphonuclear and NK cells engage with BKPyV 
targets and elicit a pronounced inflammatory response typical for late onset of HC. 
 
3.1.2.4.2.3 PyVHC Treatment Strategies 
 
Therapy for PyVHC is challenging and purely supportive, consisting mainly of pain relief, 
bladder irrigation to prevent clot formation, hyperhydration to increase diuresis and 
urosurgical intervention (153). Additionally, lost platelets and red blood cells are substituted. 
There have been reports of effective interventions with vidarabine or cidofovir (180, 181). 
However, renal drug toxicity is a critical issue in stem-cell transplant patients, which calls for 
a cautious use of cidofovir. Interestingly, hyperbaric oxygen is frequently used for radiation 
induced haemorrhagic cystitis and has also been reported to be beneficial for patients with 
PyVHC (182) causing stimulation of mucosal repair in the urinary bladder. 
 
3.1.2.4.3 Other BKPyV-Related Diseases 
 
BKPyV can also cause other diseases, such as ureteric stenosis found in kidney transplant 
recipients and in allogeneic HSCT patients (4, 183-185). Few reports describe some cases of 
BKPyV influence on CNS diseases among immunocompromised patients (186, 187). There 
are also reports on detection of BKPyV proteins and/or DNA in some tumors (188). However, 
a definitive causal role for BKPyV in human malignancy is still missing (189, 190). 
30 
 
3.2 Immune Response to Viral Infection 
 
All living organisms have developed several kinds of mechanisms to protect themselves from 
invasion by microorganisms, including viruses (191). The main function of immune system is 
the recognition and distinction of self and non-self antigens (192-194). The mammalian 
immune system can be generally divided into two parts: (1) the innate or non-specific 
immunity, which is a first line of defense causing immediate not antigen-specific response 
against invading organisms, and does not demonstrate immunological memory; (2) the 
adaptive or specific immunity, which is a second line of defense causing delayed antigen-
specific response against invading organisms, and demonstrates immunological memory 
(195).   
 
3.2.1 Innate Immune Response to Viruses 
 
Body surfaces like skin, mucosa or surfaces within the body, including endothelial cells and 
basement membranes, are typical anatomic barriers, which are partly effective in preventing 
virus entry and its spread within the host organism (196). Under normal conditions, these 
barriers have a low permeability for viruses provided that the body surfaces stay intact. 
However, viruses can sometimes penetrate endothelial border by replicating in the capillary 
endothelial cells or in circulating leukocytes (197-202). Additionally, most of body fluids and 
tissues contain soluble viral inhibitors, including chemically diverse lipids, polysaccharides, 
proteins, lipoproteins and glycoproteins, which prevent viral attachment, inactivate virus or 
inhibit virus replication (203, 204). In the gastrointestinal tract, some viruses can be also 
inactivated by acid, bile salts and enzymes (204, 205).  
The complement system is one of the major effector mechanisms of the innate immune 
response. It is complex network of more than 30 plasma and membrane-associated serum 
proteins, constituting more than 15% of the globular fraction of plasma which can elicit 
cytolitic immune responses against the virus (206, 207). All complement proteins are 
organized into a hierarchy of proteolytic cascades that start when pathogenic surfaces are 
identified. The recognition of an antigen leads to generation of potent proinflammatory 
mediators (anaphylatoxins), opsonization of the pathogenic surface through various 
complement opsonins (e.g., C3b), targeted lysis of the pathogenic surface through the 
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assembly of membrane-penetrating pores known as the membrane attack complex (MAC), 
as well as production of classical proinflammatory response molecules, e.g. interferons (206).  
Type I interferons (IFNs) are the principal cytokines involved in the antiviral response and 
can be produced by all nucleated cells (208). Some members of type II and III IFNs have also 
been shown to play a role in blocking viral DNA synthesis (209-211). Despite different 
receptors for each of these IFNs, they share downstream signaling molecules and initiate a 
signaling cascade through the Janus kinase (JNK) signal transducer and activator of 
transcription (JAK-STAT) pathway. The activation of this pathway leads to the transcriptional 
regulation of hundreds of IFN-regulated genes (IRGs) including the signal transducer and 
activator of transcription (STAT) and IFN regulatory factor (IRF) families of transcription 
factors, which are involved in the regulation of both ISG and IFN gene expression (212, 213). 
This leads to a remarkable antiviral state, effective against positive-, negative-, and double-
stranded RNA viruses, DNA viruses, and intracellular bacteria and parasites. Therefore, IFNs 
have multiple functions: (1) they increase expression of proteins responsible for the 
apoptosis of virus-infected cells, including TNF-alpha related apoptosis inducing ligand 
(TRAIL/Apo2L), Fas/FasL, XIAP associated factor-1 (XAF-1), caspase-4, caspase-8, dsRNA 
activated protein kinase (PKR), 2'5'A oligoadenylate synthetase (OAS), death activating 
protein kinases (DAP kinase), phospholipid scramblase, galectin 9, IFN regulatory factors 
(IRFs), promyelocytic leukemia gene (PML) and regulators of IFN induced death (RIDs) (214, 
215); (2) they activate NK cells and DCs and trigger the adaptive immune response (216).  
The cells involved in the innate immune response include natural killers (NKs), dendritic cells 
(DCs), macrophages, γ/δ-T lymphocytes, neutrophils, basophils, and eosinophils (191). These 
cells express a set of germline encoded pattern recognition receptors (PRRs) that are able to 
recognize conserved molecular patterns associated with viruses (191, 196, 217-219). These 
receptors trigger a rapid inflammatory response by production of proinflammatory cytokines 
and chemokines, thereby inducing the killing of infected/transformed cells or stimulating 
phagocytosis or apoptosis. They can also upregulate expression of co-stimulatory molecules 
responsible for activation of the adaptive arm of the immune responses. Another essential 
function of PRRs is discrimination between self and non-self nucleic acids. According to 
recent reports on innate immunity this discrimination relies mostly on Toll-like receptors 
(TLRs), retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), and nucleotide-binding 
oligomerization domain (NOD)-like receptors (NLRs).  
TLRs are single, membrane-spanning receptors on sentinel cells such as macrophages and 
dendritic cells, that recognize structurally conserved molecules derived from pathogens. TLR 
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mediate the antiviral immune responses by recognizing virus infection, activating signaling 
pathways and inducing the production of antiviral cytokines and chemokines. TLRs 1, 2, 4, 5, 
and 6 are located primarily in the plasma membrane and therefore interact with 
components of microbial pathogens that come into contact with the cell. In contrast, TLRs 3, 
7, 8, and 9 are situated in the membranes of endosomes and lysosomes. The extracellular 
domain with ligand-binding site is exposed inside these organelles. Genomic material 
derived from endocytosed pathogens can be bound by TLRs and trigger immune response. 
After binding their respective ligands, TLRs 3, 4, 5, 7 and 9 send the signal through their 
homodimers. However, TLR2 may heterodimerize with TLR1 or TLR6 depending on the 
ligand. TLR4 requires in addition MD2 for signal transduction (Fig. 11).  
 
 
Figure 11. Cellular distribution of TLRs and their recognized molecules. 
 
Although TLR2 has been best studied in the context of antibacterial and anti-fungal 
responses, it has been also shown in a limited number of cases to be involved in the 
recognition of DNA viruses, e.g. by recognition of envelope glycoproteins B and H of human 
cytomegalovirus (HCMV) or glycoproteins gH/gL and gB of herpes simplex virus (HSV) (220-
224). Therefore it is believed that it might be also involved in recognition of other DNA 
viruses. However, the most important member of the TLR family able to detect viral DNA is 
TLR9. This receptor is primarily expressed in B cells and plasmacytoid dendritic cells (pDCs). 
The main function of TLR9 is to recognize viruses containing genomes rich in CpG DNA 
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motifs, which is commonly found in prokaryotes and viruses but not in vertebrates. Studies 
have shown that TLR9 is involved in recognition of hepatitis B virus (HBV), murine 
cytomegalovirus (MCMV) and Epstein-Barr virus (EBV) (225, 226). After recognition of 
cytoplasmic viral DNA, TLR9 recruits its adaptor protein MyD88 to initiate two signaling 
pathways in pDCs. MyD88 interacts with IRF7 resulting in IRF7 phosphorylation by the 
serine/threonine kinases IRAK-1 and IKKα. Phosphorylated IRF7 is translocated into the 
nucleus in order to induce the transcription of type I IFN genes (227, 228). MyD88 is also 
associated with TRAF6 which interacts with IKK kinase complex resulting in IKK activation by 
phosphorylation (229). The activated IKK initiates  inhibitor of κB (IκB) phosphorylation at 
specific NH2-terminal serine residues. Phosphorylated IκB is then ubiquitinated, thereby 
releasing NF-κB dimers from the cytoplasmic NF-κB-IκB complex allowing them to 
translocate to the nucleus, binding to κB enhancer elements and inducing transcription of 
proinflammatory genes (230-232). Upon stimulation by viral nucleic acids, TLR9 is 
transported to the early endosomes to activate the NF-κB. Once activated, it is able to 
induce cytokine genes in dendritic cells (DCs) and subsequently traffics to lysosome-related 
organelles (LRO) to induce type I IFNs (230, 233). Also RLRs can trigger signal that induces 
type I IFNs and other inflammatory cytokines through the IPS-1 adaptor molecule (234, 235).  
Dendritic cells (DCs) are antigen-presenting cells, whose main function is to process an 
antigen and present it on the cell surface to the T cells of the immune system. They act as 
messengers between the innate and the adaptive immune system.  
Macrophages are another type of innate immune cells, which can act as messenger for the 
adaptive immune system. Along with dendritic cells, they are foremost among the cells that 
present antigens, playing a crucial role in initiation of an immune response. As secretory 
cells, monocytes and macrophages are vital to the regulation of immune responses and the 
development of inflammation. They produce a wide array of chemical substances including 
enzymes, complement proteins, and regulatory factors such as interleukin-1 (IL-1).  
Natural Killer (NK) cells are another key component of innate immunity. They display an 
antigen-independent lytic activity (236). NK effector functions are controlled by a balance of 
activating and inhibitory signals provided by killer-cell immunoglobulin-like receptors (KIRs) 
through the interaction with specific Human Leukocyte Antigen (HLA)-class I ligands. In HSCT 
recipients, the role of NK cells in mediating graft-versus-leukemia effect and in controlling 
infections has been well described, but little is still known about NK cells in solid organ 
transplantation (237). It has been observed that NK cells are able to suppress graft-versus-
host disease (GVHD). It has been also shown that donor T cells exhibited less proliferation 
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and decreased IFN- production in the presence of NK cells (238, 239). In vivo studies 
revealed perforin- and Fas ligand (FasL)-mediated reduction of donor T cell proliferation and 
increased T cell apoptosis in the presence of NK cells (238). In vitro, activated NK cells 
mediate direct lysis of reisolated GVHD-inducing T cells (238). The correlation between KIRs 
genotype and viral infection following kidney transplantation has been described for CMV 
(240). HLA-C/KIR interactions were associated with the control of primary CMV infection as 
measured by the time to CMV viremia in CMV D+/R- solid organ transplant recipients. The 
presence of the activating receptor (KIR2DS2) in combination with a weaker inhibitory 
receptor (KIR2DL3 on at least one allele) was associated with protection against CMV 
viremia. However, this protective effect was only present if neither the donor nor the 
recipient expressed any HLA-C2 molecules (240). Another study showed significantly 
reduced rate of CMV viremia in kidney transplant recipients carrying KIR B haplotypes in the 
subpopulation of kidney transplant recipients (241). In contrast, a lack of such association 
has been observed for BKPyV reactivation (237). A recent study reported a genetic 
predisposition to BKPyV infection and PyVAN development by demonstrating a protective 
effect of the activating receptor KIR3DS1 as it has been shown for other viruses such as 
human papillomavirus (HPV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) 
and CMV (242). 
Although it is well known that the spleen plays a key role in detection and clearance of 
pathogens from blood, these processes are redundant with immune surveillance by other 
tissues. With the exception of clearance of encapsulated bacteria by the spleen, the host's 
ability to detect and clear pathogens is not affected by splenectomy (243). Such functional 
redundancy is not seen for immune surveillance mediated by the liver, suggesting this organ 
is a primary surveillance mechanism for intravascular infections (244). By receiving both 
portal vein blood and arterial blood, the liver is an important and critical component in the 
defense against blood-borne infection due to innate and adaptive immune cells specialized 
in detection and capture of pathogens from the blood. Additionally, these immune cells 
participate in coordinated immune responses leading to pathogen clearance, leukocyte 
recruitment and antigen presentation to lymphocytes within the vasculature. The role of 
liver in host defense has to be tightly regulated to ensure that inappropriate immune 
responses are not raised against non-pathogenic exogenous blood-borne molecules, e.g. 
food. Therefore, this characteristic for the liver balance between activation and tolerance 
makes the liver a frontline immunological organ (244). The liver contains the largest 
population of macrophages (resident liver macrophages, namely Kuffler cells (KCs)) and NK 
35 
 
cells. The role of the liver in detection and response to infectious organisms is a function of 
not only the population of cells residing in this organ, but also specific anatomy. Liver 
sinusoidal endothelial cells (LSECs) play a major role in pathogen detection, capture and 
most probably antigen presentation. LSECs comprise approximately 50% of the non-
parenchymal cells in the liver, meaning more than twice more abundant than either 
macrophages or lymphocytes in the liver (245). LSECs separate the underlying hepatocytes 
from the blood in the sinusoidal lumen. Due to lack of organized basement membrane there 
is a gap between the endothelial lining and hepatocytes, called the space of Disse. This 
physical separation serves to limit direct contact between the liver parenchyma and the 
sinusoidal lumen (246). The LSECs can selectively regulate the passage of molecules from the 
sinusoid lumen to the space of Disse and the underlying hepatocytes, and facilitate direct 
contact between hepatocytes and intraluminal lymphocytes (246). LSECs are also important 
immune APCs due to expression of wide variety of PRRs, including Toll-like receptors TLR3, 
TLR4, TLR7 and TLR9 (247, 248). Furthermore, LSECs constitutively express major 
histocompatibility complex (MHC) I and MHC II, costimulatory molecules (CD80 and CD86) 
and adhesion molecules (such as ICAM) needed for interaction with lymphocytes (248). 
Surface scavenger receptors, mannose receptors and receptors for immunoglobulins and 
immune complexes, enable LSECs to directly internalize antigens, cellular debris and 
immune complexes of the size up to 1 μm in diameter (248, 249). Innate immune responses 
in the liver are summarized in Figure 12. 
 
 
 
Figure 12. Innate immune responses in the liver [from (244)] 
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3.2.1.1 Specific Viral DNA sensors 
 
So far, several candidates of viral DNA sensors together with their signaling pathways have 
been reported (250, 251).  
The first protein suggested being a cytoplasmic DNA sensor is DNA-dependent activator of 
interferon-regulatory factors (DAI). Overexpression of DAI enhances the induction of type I 
IFN by cytosolic DNA from different sources including bacterial and mammalian DNA. 
Moreover, DAI knockdown experiments point out that HSV infection also induces type I IFN. 
Recently, it has been also reported that DAI is an important partner of receptor-interacting 
protein kinase (RIP) 3 and is essential for murine cytomegalovirus (MCMV)-induced cell 
death (252). DAI partners with RIP3 and induces RIP3 binding to RIP homotypic interaction 
motif (RHIM) and RHIM-dependent necrosis. Expression of DAI sensitizes cells to virus-
induced necrosis and DAI knockdown or knockout cells are resistant to this death pathway 
(252). 
Although RIG-I is well known as an RNA-binding protein, some study reported that RLRs, 
including RIG-I and MDA5, might also act as DNA-binding proteins. Two groups identified 
RNA polymerase III as a cytosolic DNA sensor, which subsequently activates the induction of 
type I IFNs through the RIG-I pathway (253). Both studies demonstrated that AT-rich dsDNA 
serves as a template, which is consequently converted into dsRNA by RNA polymerase III. 
The transcript acts as a preferred ligand of RIG-I and as a result induces IFN-β through the 
RIG-I pathway (253). Moreover, it has been shown that HSV-1 and EBV all trigger the RNA 
polymerase III-mediated induction of type I IFNs (253). Recognition of dsRNA intermediates 
produced by RNA polymerase III-mediated transcription of dsDNA by RIG-I could be 
therefore the possible mechanisms of innate immune detection of DNA viruses. It has been 
shown that PyVAN innate immune mechanisms through TLR3 and RIG-I are responsible for 
both anti-BKPyV responses and inflammatory events. These mechanisms might therefore 
contribute to PyVAN development due to enhanced expression of cytokines and chemokines 
(254). 
MITA (Mediator of IRF3 Activation, or STING [Stimulator of Interferon Genes]) was identified 
as an important adapter protein for virus-triggered type I IFN induction. MITA occurs on the 
outer membranes of mitochondria and ER. In certain cell types, MITA is recruited to VISA 
and RIG-I upon RNA virus infection. MITA can also recruit serine/threonine-protein kinase 
TBK1 and IRF3 to the complex, in which TBK1 phosphorylates IRF3 (255). It has been shown 
that IFN-β production in response to the infection of HSV-1 or transfection of purified DNA 
from Escherichia coli is abolished in mouse embryonic fibroblasts (MEFs) with MITA 
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deficiency, suggesting that MITA is crucial in mediating DNA-induced innate immune 
responses (256). Mice with MITA knockout failed to produce type I IFNs upon infection with 
Listeria monocytogenes, or treatment with c-di-GMP in vivo. 
Another protein called IFI16, containing a C-terminal HIN-200 domain for DNA binding and 
an N-terminal pyrin domain (PYD) for protein-protein interaction, binds to both ss and ds 
DNAs. The subcellular localization of IFI16 differ in different cell types and can be detected in 
nucleus, cytoplasm or both (257). The cytoplasmic activated IFI16 recruits MITA, which 
phosphorylates IRF3. Phosphorylated IRF3 activates NF-κB and induces IFN-β production, 
resulting in inhibition of HCMV replication. Furthermore, knockdown of IFI16 inhibits DNA- 
and HSV-1-mediated activation of IRF3 and NF-κB (258, 259). When localized in the nucleus, 
IFI16 functions as a nuclear sensor to recruit ASC (apoptosis-associated speck-like protein 
containing a CARD) via their respective PYD domain and therefore induce the formation of 
inflammasomes. However, further studies are required in order to understand the 
significance of the nuclear IFI16-inflammasomes (250, 251).  
DDX41, a member of DEXDc family of helicases, has also been suggested as a cytosolic 
sensor for DNA virus (260). It has been shown that DDX41 is responsible for cytosolic DNA 
sensing in human mDCs (myeloid dendritic cells), BMDCs (bone marrow derived dendritic 
cells) and monocytes. DDX41 can also bind to poly-AT or HSV-1 DNA, resulting in its 
interaction with MITA and activation of TBK1 (260).  
LTTFIP1 can possibly also take part in non-self DNA recognition. It is able to detect the 
infection of vesicular stomatitis virus (VSV) in macrophages. Moreover, its knockdown 
inhibits VSV-induced production of IFN-β (261). After recognition of dsRNA, B-DNA or Z-DNA 
in the cytoplasm, LRRFIP1 promotes the activation of β-catenin, which binds to the C-
terminal domain of IRF3 and recruits the acetyltransferase p300 to induce the expression of 
IFN-β (261). However, more studies are needed to establish a specific role of LRRFIP1 in 
innate immune recognition of DNA viruses in vivo. 
Recently, high-mobility group box (HMGB) proteins have been also reported to sense non-
self nucleic acids. The family includes highly conserved HMGB1, 2 and 3. Each protein 
contains two DNA binding domains. Whereas HMGB1 is ubiquitously and abundantly 
expressed, the expression of HMGB2 and HMGB3 are limited to lymphoid organs and 
hematopoietic stem cells. While HMGB1 and HMGB3 have been suggested to recognize both 
cytosolic DNAs and RNAs, HMGB2 recognizes only cytosolic DNAs. HMGB1 deficiency results 
in reduction of type I IFNs as response to both DNA and RNA, whereas HMGB2 deficiency 
only affects DNA-triggered induction of type I IFNs in MEFs.  
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LSm14A, has been also demonstrated as a sensor of viral nucleic acids in the early phase of 
viral infection (262). LSm14A is translocated to peroxisomes upon infection by both RNA and 
DNA viruses. In the peroxisomes, LSm14A binds MITA to induce IFN-β as a response to DNA 
viruses, leading to the recruitment of RIG-I and VISA thereby inducing IFN-γ in response to 
RNA viruses (262). The constitutively expressed LSm14A may act as the earliest sensor of 
viral nucleic acids. Therefore, it has been assumed that P-bodies are important cellular 
structures involved in viral life cycles (263). Interestingly, a recent study shows that 
nonstructural protein (NS1) of influenza A virus inhibits cellular antiviral response by 
targeting the P-body-localized LSm14A/RAP55 (264). These findings indicate an important 
role of LSm14A as well as the P-bodies in cellular antiviral response. 
Besides the activation of TBK1 and IRF3, which results in the induction of type I IFNs, innate 
recognition of viral DNA also activates pathways leading to the assembly of inflammasomes, 
which, via caspase-1, result in the cleavage and maturation of certain proinflammatory 
cytokines such as IL-1β and IL-18 (265). So far, four types of inflammasomes have been 
identified, including the NLRP1, NLRP3, IPAF, and AIM2. Whereas NLRP1- and IPAF-
inflammasomes mainly function against bacterial infection, AIM2 was reported to be a 
regulator of DNA-mediated inflammatory responses (266). AIM2 contains a conserved DNA 
binding domain and a PYD domain. It has been reported that AIM2 directly senses dsDNA 
from both bacteria and virus in the cytoplasm and recruits the adaptor protein ASC that 
interacts with pro-caspase-1. Procaspase-1 is activated in this complex, leading to the 
processing and maturation of inflammatory cytokines, like IL-1β and IL-18 . Such AIM2-ASC-
Caspase-1 complex is called AIM2-inflammasome. Since the expression of AIM2 is induced 
by IFNs, it is likely that after DNA virus infection the host cells utilize both the TBK1-IRF3 and 
AIM2-inflammasome pathways to ensure a fulfilled innate response against viral infection. 
Defensins are small cationic peptides that intrinsically possess antimicrobial properties and 
are key mediators of the innate immune system (267). It had been proposed that defensins 
primarily target enveloped viruses by disrupting the envelope membrane in a manner similar 
to their antibacterial activities. However, the recent studies demonstrates that defensins 
exhibit complex functions by positively or negatively modulating infection of both enveloped 
and non-enveloped viruses (267). Human defensins are classified into two subfamilies,  and 
, which differ in their three disulfide bond paring. Neutrophil -defensins (HNPs 1-4) are 
synthesized in promyelocytes and the mature peptide is stored in primary granules of 
neutrophils (267). However, HNPs 1–3 can also be found in other immune cells, including 
natural killer cells, B cells, T cells, monocytes, macrophages and immature dendritic cells. 
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Two additional human -defensins, human defensins 5 and 6 (HD5 and HD6), are 
constitutively expressed in intestinal Paneth cells but also found in the genital mucosa.  
HNP release can be induced by chemokines, FC receptor cross linking, phorbol myristate 
acetate and bacterial components that activate Toll-like receptors (TLR) 2 and 5. Human -
defensins (HBDs) 1–3 are expressed by epithelial cells, monocytes, macrophages and 
monocyte-derived dendritic cells. HBDs expression can be induced by viruses, bacteria, 
microbial products, Toll-like receptor (TLR) ligands, EGF and pro-inflammatory cytokines. It 
has been shown that defensins are frequently induced in response to viral infection (268-
270). Recent studies revealed that HD5 neutralizes JCPyV infection at early post entry step in 
the viral cycle by stabilizing the viral capsid and disturbance of JCPyV trafficking (271). The 
same effect of HD5 has been observed for BKPyV. However, due to different receptors in 
comparison to JCPyV, disturbance of virus trafficking occurs at the entry level thereby 
preventing virus entry to the host cell (272). 
In conclusion, only few studies have been performed to investigate innate immune 
responses to JCPyV and BKPyV (237, 242, 254, 271, 272). Since both viruses, similarly to 
other polyomaviruses, have dsDNA as a genome, all above described DNA sensoring 
mechanism should be taken under consideration whilst speculation about the innate 
immunity to HPyV. 
The innate immune response makes a crucial contribution to the activation of adaptive 
immunity. The inflammatory response increases the flow of lymph containing antigen and 
APCs into lymphoid tissues, while complement fragments on virus surface together with 
cells which have taken up the virus provide signals to activate lymphocytes, which receptors 
bind to presented antigens.  
  
3.2.2 Adaptive Immune Response to Viral Infection 
 
The induction of the adaptive immune response is activated once the virus is ingested by 
immature dendritic cells (DCs). These specialized phagocytic cells are localized in most 
tissues. The immature DCs carry receptors on its surface that recognize common features of 
many pathogens which enable DCs to engulf pathogen and degrade it intracellulary. When a 
DC takes up a pathogen in infected tissue, it becomes activated, and travels to a nearby 
lymph node. Viruses do not carry invariant molecules similar to those of bacteria and are 
rarely directly recognized by macrophages. However, viruses can still be taken up by 
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dendritic cells through nonreceptor-depending process. Antigens can then be presented to 
the lymphocytes (Fig. 13). Each naive lymphocyte entering the bloodstream bears antigen 
receptor of a single specificity. This specificity is determined by unique genetic mechanism 
that operates during lymphocyte development in the bone marrow and thymus to generate 
numerous different variants of the genes encoding the receptor molecules. Lymphocytes 
undergo a process akin to natural selection and only those lymphocytes that encounter an 
antigen to which their receptor binds will be activated to proliferate and differentiate into 
effector cells. Clonal selection of lymphocytes is the most important principle of adaptive 
immunity. The lymphocyte population comprises of the thymus-derived lymphocytes (T 
lymphocytes), bone-marrow-derived (B lymphocytes), and the natural killer cells (NK cells). 
T-lymphocytes mediate the cellular immunity and require thymus to mature before being 
deployed to the peripheral lymphoid organs for further antigen-mediated differentiation. A 
small subset of the CD4+ cells, including natural regulatory cells and NK cells are already 
distinct differentiated cells on release from the thymus. CD4+ T cells, along with CD8+ T cells, 
comprise the majority of T-lymphocytes. CD4 T cells recognize approximately 17 amino acid 
peptides presented by APCs on MHC class II. After being activated and differentiated into 
distinct effector subtypes CD4+ T cells play a major role in mediating immune response 
through the secretion of specific cytokines. The CD4+ T cells carry out multiple functions, 
ranging from activation of the cells of the innate immune system, B-lymphocytes, cytotoxic T 
cells, as well as nonimmune cells, and also play critical role in the suppression of immune 
reaction. The subset of CD4+ helper T cells remaining in the lymphoid organ helps B 
lymphocytes to respond to the microbial antigens. CD8+ T cells are stimulated by 10 amino 
acid peptides on MHC class I molecule of APCs. As a result of clonal expansion, activated 
CD8+ T cells rapidly increase from virtually undetectable in the naive host to levels that are 
readily detectable. CD8+ T cells are typically cytotoxic and express enzymes such as perforin, 
granzyme and granulysin. After clearance of the virus CD8+ T cells decline in number to a 
memory level. Memory CD8+ T cells may be present lifelong and are able to mount rapid, 
heightened responses to reinfection with the certain virus. 
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Figure 13. Adaptive immune responses to viral infection. 
 
The critical event in antigen recognition by T cells is the manner the antigenic peptides are 
presented and thus recognized by the T cell receptor (TCR). The main molecules presenting 
antigen peptide are major histocompatibility complex (MHC) molecules, divided into two 
classes: MHC class I and II. They deliver peptides from two diverse intracellular 
compartments reflecting the origin of the antigen which is processed: either intracellular or 
taken up from the outside of the cell. MHC molecules are glycoproteins localized on the cell 
surface. These two classes of MHC molecules differ both in function, structure and cell 
distribution. While MHC class I is present on all nucleated cells, MHC class II are present 
mostly on specialized antigen-presenting cells. 
The MHC class I molecules bind peptides derived from virus-encoded proteins in a size of up 
to 10 amino acids in size. Such peptides are mainly formed through degradation of cytosolic 
proteins by the proteasome and translocated to the ER by proteins called transporters 
associated with antigen processing-1 and -2 (TAP1 and TAP2) where they associate with 
MHC class I complex (273). At this stage, the fully folded MHC class I-peptide complex is 
released from the TAP complex in the ER and is transported to the plasma membrane, 
where the peptides are presented to appropriate CD8+ T cells (Fig. 14a). 
The MHC class II molecules bind extracellular antigens comprised of up to 17 amino acids. 
This occurs usually in specialized APC. Extracellular proteins are endocytosed and due to low 
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pH, endosomal and lysosomal proteases are activated and degrade the proteins into 
peptides, followed by their binding by MHC class II molecules. During their synthesis in the 
endoplasmic reticulum, MHC class II molecules are covalently bound to a polypeptide called 
the invariant chain (274). The invariant chain protects MHC class II molecule from binding 
unwanted peptide and targets the MHC class II-invariant chain complex to the endosomal 
compartment, where the invariant chain is replaced with the antigen peptide. The peptides 
are presented to CD4+ cells on the membrane surface of APC (Fig. 14b). 
Thus, MHC class I-peptide complexes activate CD8+ T cells committed to kill, while MHC class 
II-peptide complexes activate CD4+ T cells aimed at activating macrophages (Th1 cells) or B 
cells (Th2 cells).  
 
 
Figure 14. Different antigen-processing pathways for the MHC class I and class II molecules 
[from (275)] 
 
However, dendritic cells can endocytose antigens from other cells and cross-present them to 
CD8+ cytotoxic T lymphocytes. Cross-presentation is of particular importance, because it 
permits the presentation of exogenous antigens, which are normally presented by MHC class 
II on the surface of infected dendritic cells to be also presented by MHC class I without 
infecting the dendritic cell. Cross-presentation allows the dendritic cell to avoid using the 
endogenous proteasomal processing pathway, which otherwise would divert cellular 
resources away from MHC class II presentation processes that present endogenous antigens 
after infection. Such a diversion could functionally impair the dendritic cell (Fig. 14c). 
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Another important lymphocytes are B cells, or bone marrow-derived lymphocytes. They 
comprise up to 20% of all circulating peripheral lymphocytes, but can be also found in bone 
marrow or other lymphoid tissues, including spleen, lymph nodes, and tonsils. Produced in 
the bone marrow B cells can migrate to the spleen and lymph nodes in order to mature and 
differentiate into immunocompetent B cells. B cells are responsible for generating 
antibodies to specific antigens, which they bind via B cell receptors (BCR). Activation of B 
cells occurs through antigen recognition by BCRs and a required co-stimulatory, secondary 
activation signal from either helper T cells or the antigen itself. This results in in B cell 
proliferation and formation of germinal centers where B cells differentiate into plasma cells 
or memory B cells. Importantly, all B cells derived from a specific progenitor B cell are clones 
that recognize the same antigen epitope. Plasma cells are found in the spleen and lymph 
nodes and are responsible for secreting different classes of clonally unique antibodies. 
Following the primary response, a small number of B cells develop into memory B cells, 
which express high-affinity surface immunoglobulins (mainly IgG), survive for a longer period 
of time, and enable a rapid secondary response. 
B cells are the only cells producing antibodies in order to mediate humoral response. Upon 
stimulation with viral antigen, B cells differentiate into plasma cells and secrete large 
amounts of antibodies. The antibodies circulate in the bloodstream and permeate the other 
body fluids, where they specifically bind to the antigen of a pathogen and mark it for 
elimination by phagocytosis. After the response, some of the B cells differentiate into 
memory B cells, which are ready to rapid response in case of re-exposure to the viral antigen. 
The antibody response is most of the time directed to the structural proteins of the virus 
(276). However, usually not all of the elicited antibodies have neutralizing activity, which 
inhibit the viral infection (277, 278). Neutralization is often considered as the most efficient 
mode of antibody-mediated defense against viral infections. During neutralization 
antibodies interfere with virion in many different ways including blocking viral receptors, 
inhibiting uptake into cells, preventing uncoating of the genomes in endosomes, or causing 
aggregation of virus particles. All of these mechanisms lead to virus neutralization (Fig. 15a). 
However, effector functions mediated by virus-specific non-neutralizing antibodies can also 
have a substantial impact on virus clearance (279, 280). Non-neutralizing antibodies can still 
bind to the virus/infected cell and are able to lyse the virus/infected cell  through activation 
of complement (complement-dependent lysis). Polymerization of specific activated 
complement components on a foreign cell or enveloped virus leads to the formation of 
pores. The lipid bilayer of the cell or (enveloped) virus is disrupted (281) (Fig. 15b). 
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Antibodies can also cause opsonization, by which the marked virus is ingested and destroyed 
by a phagocyte (282) (Fig. 15c). Antibody-coated virus can be killed by a cytotoxic effector 
cell through a non-phagocytic process, characterized by the release of the content of 
cytotoxic granules or by the expression of cell death-inducing molecules (Fig. 15d). Effector 
cells that mediate ADCC include natural killer (NK) cells, monocytes, macrophages, 
neutrophils, eosinophils and dendritic cells (283).  
 
Figure 15. Different antibody strategies to combat a virus [modified from (276)] 
 
3.2.2.1 Adaptive Immune Response to HPyVs 
 
Polyomaviruses belong to the group of infectious non-self agents delivering PAMPs that are 
recognized by cell surface pattern recognition receptors PRRs on APC (192-194, 196, 284).  
T cell immunity to polyomaviruses has been studied mostly for LTag and capsid protein VP1 
(285-297). LTag is very suitable to examine due to its immunogenicity and capability to 
stimulate both T and B cell responses (298). T cell responses to LTag have been studied in 
selected healthy humans by stimulating isolated peripheral blood mononuclear cells 
(PBMCs) with purified SV40 LTag. Eventually all responded by T cell proliferation and T cell 
lines could have been established by LTag and nucleosome-LTag complexes (298, 299). 
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Because LTag from BKPyV, JCPyV and SV40 demonstrate approximately 75% amino acid 
homology, it might be that the data obtained for SV40 LTag do not reflect a high incidence of 
SV40 infected individuals, but more likely that most individuals have cross-reactive LTag-
specific memory T cells (298-301). The T cell responses were caused by CD4+ T cells, as 
demonstrated by a substantial decrease in proliferation upon adding human anti-CD4 
antibodies to the cultures prior to antigenic stimulation and weak proliferation reduction 
after anti-CD8 treatment (300). Similar results have been observed in mice after 
immunization with SV40 LTag (298). The established CD4+ T cell lines had the potential to 
induce low level anti-LTag antibody production in vitro when cocultured with highly purified 
autologous B cells (302). It has been reported that all of healthy BKPyV seropositive 
individuals had T cells proliferating in vitro as a response to antigens prepared from BKPyV-
infected fibroblasts, whereas this was not the case for seronegative individuals (303). It has 
been also reported that BKPyV replication in healthy individuals and in immunosuppressed 
patients is controlled by CD8+ and CD4+ T lymphocytes (285, 297, 304).  
A recent study investigated circulating BKPyV-specific T cells in healthy donors (HDs) by 
using VP1 antigen to identify BKPyV-specific CD8+ T cells (296). BKPyV VP1-specific T cells 
circulate in the peripheral blood at low levels. Moreover, they display a resting memory 
phenotype and are polyfunctional upon stimulation in terms of cytokines production (296). 
These results consorts with lack of the virus in the blood but virus presence in distal sites, 
urinary tract and kidneys, implying that circulating T cells are lacking BKPyV specific-
stimulation for large periods of time. Additional in vitro studies showed that pulsing of 
monocyte-derived dendritic cells with inactivated BKPyV or peptide pools covering either 
structural or regulatory BKPyV proteins results in generation of BKPyV-specific T cells (305, 
306). Those BKPyV-specific T cells displayed both production of cytokines and cytotoxic 
activity. It has been reported that both VP1 and LTag responses are significantly higher in 
KTRs in comparison to healthy individuals (285, 307). Overall CD8+ T cell responses were 
identified as LTag-specific rather than VP1-specific (285). In the same study, JCPyV VP1 and 
LTag immune responses were investigated in JCPyV-seropositive KTRs and showed that in 
vitro stimulation with BKPyV VP1 peptides induce limited JCPyV VP1 responses. However, 
similar responses to BKPyV LTag and JCPyV LTag were observed after in vitro stimulation 
with BKPyV LTag peptides, suggesting that BKPyV- and JCPyV- specific immune responses 
mediated by LTag are more conserved among HPyVs than those mediated by VP1 (285). 
Furthermore, LTag-specific immune responses have been shown to be correlated with the 
recovery from viremia in KTRs (291). This comes along with results from more recent study 
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where BKPyV-specific immunity to structural and non-structural BKPyV proteins at different 
phases of BKPyV reactivation was studied in KTRs (308). T cells specific for non-structural 
proteins such as LTag were detected earlier than T cells specific for structural proteins, and 
appearance of T cells specific for non-structural proteins correlates with recovery from 
BKPyV reactivation. Therefore, immunity to non-structural proteins, and not to structural 
proteins, are thought to be a reliable marker of recovery from BKPyV viremia (308). 
The presence of JCPyV-specific CD8+ cytotoxic lymphocytes among healthy and 
immunocompetent individuals seems to protect from PML development (309-312). It has 
been also shown that CD8+ T cell response was significantly lower in PML progressors in 
comparison to survivors (313). Additionally, an early detection of JCPyV-specific CD8+ T cells 
in PML patients seems to be associated with a better outcome and eventual higher survival 
(314, 315). Among multiple sclerosis patients, it has been shown that natalizumab treatment 
preventing T cell homing to the brain does not impair peripheral JCPyV-specific T cells 
responses and even increase JCPyV-specific memory or effector responses in some patients 
after 12 months of therapy (316). The presence of CD4+ T cells seems to be necessary for an 
efficient immune control of PML (313). Individuals with low CD4+ T cell numbers, including 
HIV-AIDS patients or individuals with idiopathic CD4+ lymphocytopenia, have a higher risk of 
developing PML and a lower survival rate (310, 315, 317). Estimated 1-year survival was 48% 
in HIV+ patients with PML with CD4 count less than 200/µl at PML diagnosis compared to 
67% in those with CD4 more than 200/µl (315). Nevertheless, PML does not affect all HIV 
patients with very low CD4+ T cells counts (90). Surprisingly, individuals with a low CD4+ T cell 
activity showed very strong humoral response against JCPyV. This phenomenon might be 
explained either by a T cell-independent virus-specific antibody production or by the 
establishment of B cell memory directly after primary infection (310, 318).  
Cellular immune responses directed against the VP2 and VP3 capsid proteins and regulatory 
(sTag, Agno) proteins have also been investigated (296, 307, 308, 319-321). It has been 
demonstrated that VP2, VP3 and sTag proteins are targets of JCPyV and BKPyV-specific 
immune responses in healthy donors, KTRs and PyVAN patients. Moreover, memory T cells 
directed against VP1, VP2, VP3, LTag and sTag have been detected in BKPyV-seropositive 
KTRs (307). In the same study, memory T cells specific for VP3 were found to be more 
prevalent than memory T cells specific for the other BKPyV proteins in patients with a PyVAN 
history (307). Despite the high expression of Agno, it seems to be ignored by the immune 
system, since only 15% of HDs and 7.5% of KTRs are Agno seropositive (320).  
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3.3 Antibody Assays for Studying Adaptive Humoral Immunity to JC and BK 
Polyomaviruses 
 
3.3.1 Technical Aspects of JCPyV and BKPyV Antibody Assays 
 
The detection of JCPyV- or BKPyV-specific antibodies can be accomplished by different 
techniques.  
Hemagglutination assay (HA) utilizes ability of JCPyV and BKPyV to bind to sialic acid 
structures; virus binds to sialic acid residues on RBCs and forms a lattice (hemagglutination) 
and can be used for rapid determination of level of virus in a sample. RBCs which are not 
bound by virus precipitate to the bottom of the well. However, the RBCs bound by the virus 
form a lattice. The titer of the virus is calculated as the highest dilution at which virus causes 
hemagglutination. The HA can be modified in order to investigate level of antibodies to 
JCPyV or BKPyV in a serum sample. The basis of hemagglutination inhibition assay (HAI) is 
that antibodies against the virus will prevent attachment of the virus to RBCs resulting in 
hemagglutination inhibition. The highest dilution of serum preventing hemagglutination is 
called hemagglutination inhibition titer. However, HAI fails to detect JCPyV with VP1 
mutations characteristic for PML. Virus with 55F, 267F, 269F and 269Y mutations cannot 
agglutinate RBCs (99). Whereas for some of the mutants, e.g. 60E, 265D and 271H, 
hemagglutination is still possible but at much lower level. Moreover, another disadvantage 
is a need of removal of unspecific inhibitors from sera prior testing. 
For neutralization test a serum sample is mixed with a viral suspension and incubated to 
allow the antibodies to react with the virus, followed by plating the mixture on virus-
susceptible cells. Depending on the virus, the results of the neutralizing test can be 
examined in different ways, including direct microscopic examination for evidence of viral 
cytopathic effect, immunofluorescent staining or reduction of plaque numbers. A modified 
virus neutralization assay, called the log serum neutralization index (LNI), can also be used to 
evaluate the potential of a serum specimen to neutralize virus infectivity. In this test 
concentration of serum stays constant while the challenge dose of the virus is increased. The 
advantage of this method is that it measures the capacity of a serum to protect from virus 
infection because serum is usually being tested undiluted. However, because the used 
serum is undiluted, routinely securing volumes of serum sufficient to perform this test is 
difficult and mitigates against general implementation of this assay. Moreover there is a 
48 
 
need to remove non-specific inhibitors which naturally occurring in sera, to standardize 
antigen each time a test is performed, and the need for specialized expertise in proper 
reading the test results (322).  
The current enzyme-linked immunosorbent assays (ELISAs) for JCPyV and BKPyV are usually 
based on either LTag or VP1 (31, 285, 302, 323-326).  VP1 can be used as antigen in in a form 
of monomers, pentamers, or virus-like particles (VLPs) (2, 99, 327-329). Alike for BKPyV, 
there are currently no data comparing JCPyV HAI, anti-VP1, anti-VLP, and anti-LTag 
responses, except from experimental tumor exposure models (320, 325, 328, 330). However, 
it can be presumed that the high-level JCPyV antibody responses are directed against the 
viral capsid proteins due to their abundance and repetitive structure (325, 331). Moreover, 
based on the reports for BKPyV, some responses to sTag can be expected (90, 325). In 
healthy individuals, these anti-N-terminal Tag responses are hidden in the background 
signals, but might become detectable after high-level PyV replication or from PyV-associated 
tumor formation (325, 330, 332, 333).  
Some studies have compared HAI and VLP-based ELISA for structural protein antibodies, but 
it becomes clear that the assays are not equivalent with respect to their immunological and 
clinical implications (334). A low percentage of tested samples showed low HAI antibody 
titers and high ELISA antibody titers to JCPyV or BKPyV (335). The reasons for these 
discordant results are unknown. However, it could be that antibody responses to epitopes 
other than those involved with HAI or to strain differences between the virus initiating an 
infection and that used in antibody assays. The major points of each antibody testing 
include: (1) choice, preparation, and the purity of antigens; (2) background reactivity; (3) 
definition of analytically significant and clinically relevant results; (4) detection and 
interpretation of different antibody classes and subclasses; (5) selection of most appropriate 
testing method; (6) appropriate cutoff to define positive and negative test results; and (7) 
sensitivity and specificity influenced by conformation of the epitopes (2, 71). 
The choice of antigen and background reactivity has an impact on assay specificity and 
sensitivity. Therefore, the source of PyV virions or the recombinant viral antigens may 
impact the serological background activity as a result of preparative impurities from an 
expression system of choice.  
Discrimination of seropositive and seronegative samples is highly dependent on sensitivity 
and specificity of the assay and the appropriate cutoff. Sensitivity is the probability that the 
test result will be positive when the disease is present (true-positive rate). Whereas 
specificity is the probability that the test result will be negative when the disease is not 
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present (true-negative rate). A false-positive result occurs when the assay indicates the 
disease, although the disease is not present. Whereas a false-negative result occurs when 
the assay indicates the absence of disease, although the disease is present.  ELISA with low 
sensitivity or too low cutoff may result in false-positive readouts, whereas low specificity 
and too high cutoff - in false-negative readouts. This might be detrimental by 
underestimating disease risk (in case of false-negative serology result) or unnecessary 
withhold of the immunosuppressive therapy (in false-positive serology result). The antigen 
conformation is another important aspect of proper antibody testing. In recent years 
serology based on virus-like particles in enzyme immunoassays (ELISA) has become widely 
used in many viral systems, including polyomavirus infections (2, 14, 337). 
 
3.3.2 Virus-Like Particles as the Antigen in Antibody Assays 
 
Virus-like particles (VLPs) are multisubunit self-assembling protein structures with identical 
or highly related overall structure to their corresponding native viruses (338). After the first 
demonstration of the polyomavirus VP1 self-assembling into VLPs in the absence of viral 
genetic material, VLPs have been produced from a broad spectrum of enveloped and non-
enveloped viruses. Until now more than 110 VLPs have been constructed from viruses 
belonging to 35 different families (339).   
The interest in VLPs has significantly increased due to the successful development and 
introduction of HBV surface antigen and HPV capsid protein L1 as commercial vaccines 
against HBV and HPV-induced cervical cancer, respectively (340, 341). The recent reports 
describe high immunogenicity of VLPs via B cell activation and production of antibodies 
against the viral motifs presented on VLP surface (342, 343). In addition, due to a small size 
VLPs can be taken up by antigen-presenting cells and degraded, which ultimately leads to T 
cell activation (344). Moreover, due to their symmetric and highly repetitive structure, VLPs 
are capable of inducing strong humoral and cellular immune responses even in the absence 
of frequently used adjuvants (344). Furthermore, particular attention has recently been 
given to the development of new nanomaterials. This new area, called bionanotechnology, 
employs ideas and methodologies from biology, chemistry, physics, and engineering (345).  
VLPs can be produced by several expression systems (339). More than half of these systems 
employ bacterial or insect cells, other systems use yeasts (20%), mammalian (15%) or plant 
cells (9%) (339). 
Bacterial systems are mostly based on Escherichia coli  strains. E. coli  systems, based on 
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vector transformation, are generally accepted and widely used technology for VLP 
production (346). However, such a system has several disadvantages including inability to 
perform post-translational modifications of recombinant protein, their inability to generate 
the proper disulfide bonds, protein solubility problems, and the presence of endotoxins in 
the preparations of recombinant proteins (339, 341).  
In contrast to bacteria, yeasts are able to introduce post-translational modifications of 
proteins, including glycosylation, phosphorylation, acetylation, ubiquitination, sumoylation 
(347, 348). Different yeast systems have been used for the construction of numerous VLPs. 
Unfortunately, they are more complex than E. coli systems because yeast shuttle-vectors 
have to be prepared first in bacteria and only then introduced to the yeast cells as plasmid 
vectors. Moreover, yeast-based systems provide only 30% of the properly folded protein 
yield obtained in E. coli (347, 348).  
Plant systems could be a cost-effective and scalable alternative for the production of 
different VLPs in comparison to above mentioned bacteria- and yeast-based systems. One of 
the most effective plant expression systems is based on the Agrobacterium (339). It has 
been shown that tobacco and potato plants can be successfully used in production of HPV 
VLPs (349). Also transgenic tobacco has been successfully utilized for HBs antigen and HBc 
antigen VLPs (350, 351). 
More than half of all of the recombinant proteins in the pharmaceutical industry are 
produced in different mammalian cell lines (339). Alternatively, much simpler in setup insect 
cell-based system has become common for VLPs expression on laboratory or industrial scale. 
The latter is characterized by the capacity for large-scale VLP production, fast growth rates in 
serum-free media, and possible post-translational modifications similar to mammalian cells. 
Baculovirus expression systems enable generation of recombinant baculoviruses in order to 
express the protein of interest in insect cell culture (Fig. 16). The method is based on site-
specific transposition of an expression cassette into a baculovirus shuttle vector (bacmid) 
propagated in E. coli. The system comprises of: (1) pFastBac donor plasmid allowing 
generation of expression construct containing the gene of interest under control of a 
baculovirus-specific promoter; (2) E. coli host strain containing baculovirus shuttle vector 
(bacmid) and helper plasmid, and allowing generation of recombinant bacmid by 
transposition of the pFastBac expression construct; (3) Sf9 Spodoptera frugiperda insect cells 
in a liquid culture. After successful transposition, the high molecular weight recombinant 
bacmid DNA is isolated and used for transfection into insect cells. After generation of a 
recombinant baculovirus stock, it can be used to infect insect Sf9 cells for large-scale 
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expression of the recombinant protein of interest.  
  
 
Figure 16. Generation of recombinant baculovirus and expression of gene of interest using 
baculovirus expression system and Sf9 insect cells [from Bac-to-Bac Baculovirus Expression 
System User Manual] 
 
Recombinant JCPyV and BKPyV VLPs recapitulate the three-dimensional morphology of PyV 
virions as shown by electron microscopy and functionally by mediating hemagglutination 
and host cell binding (71, 335). These specific properties cannot, or can only partly, be 
mimicked by VP1 monomers and pentamers, respectively. Study on antibody responses in 
kidney transplant patients revealed significantly higher IgG ELISA levels for BKPyV VLPs in 
comparison to BKPyV VP1 monomers (352). In the same study the importance of the three-
dimensional antigen structure was experimentally confirmed by denaturation, which caused 
a drop in anti-BKPyV VLP ELISA levels, whereas anti-BKPyV VP1 levels were hardly affected 
(352). This indicates that the respective antibody binding activities are distinguishable in 
humans and suggests a lower sensitivity and specificity for VP1 compared with VLPs (352). 
There is a greater potential for VP1 monomers and pentamers to detect cross-reacting 
antibodies. It has been shown indirectly by western blot on GST and GST-VP1 fusion proteins 
of BKPyV and JCPyV by using hyperimmune rabbit serum against BKPyV. Rabbit serum 
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showed strong cross-reactivity with GST-JCPyV VP1 fusion protein, and vice versa, anti-JCPyV 
VLP rabbit serum reacted also with GST- BKPyV VP1 chimeric protein (353). In conclusion, 
although seroprevalence determined with VLP-based ELISA suggest the absence of cross-
reactivity between BKPyV-specific and JCPyV-specific antibodies, cross-reactivity may occur 
against denatured VP1 (western blot) or in assays applying monoclonal antibodies (353). VP1 
cross-reactivity may therefore complicate a routine interpretation of serological results and 
demand additional confirmatory experiments (354).  
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4 Aims of the Thesis 
 
The aims of the thesis are: 
 
1. Use of virus-like particles as a tool to study the fate of primary JCPyV and BKPyV 
viremia. 
2. Optimization of VLP-based ELISA for JCPyV and BKPyV IgG detection. 
3. Development of preadsorption inhibition assay in order to precisely define JCPyV 
and BKPyV IgG serostatus for samples with ambiguous ELISA results. 
4. Application of optimized JCPyV/BKPyV VLP-based ELISA in clinical case studies. 
5. Investigation of prognostic value of ELISA utilizing as antigen either BKPyV VP1 VLPs 
or BKPyV LTag.  
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5 Results 
5.1 Efficient Uptake of Blood-Borne BK and JC Polyomavirus-Like Particles in 
Endothelial Cells of Liver Sinusoids and Renal Vasa Recta 
 
The renourinary tract is a well-known major persistence site for JCPyV and BKPyV. However, 
the initial routes of primary infection with both viruses are not well defined. Also, the fate of 
JCPyV and BKPyV primary viremia are unclear. JCPyV and BKPyV replication is highly specific 
to the human host which precludes studies of those viruses in animal model. However, α2,6-
linked and α2,3-linked sialic acid structures serving as receptors for JCPyV and BKPyV, 
respectively, are commonly found in vertebrates, including mice. Therefore we decided to 
use a mouse model to investigate the fate of BKPyV and JCPyV in peripheral blood and their 
cellular site of uptake. Under these circumstances the mouse model simulates a non-
immune host. We utilized JCPyV and BKPyV virus-like particles (VLPs) as a model system for 
native JCPyV and BKPyV, respectively. VLPs are multisubunit protein structures with identical 
overall structure to their corresponding native viruses. It is known that overexpression of 
major capsid protein 1 (VP1) of either JCPyV or BKPyV leads to self-assembly into VLPs, 
which recapitulate the three-dimensional morphology of native virus. Four different VLPs 
were used in the study: (1) JCPyV wild-type-VP1 VLPs; (2) BKPyV wild-type-VP1 VLPs; (3) 
JCPyV L55F-VP1 VLPs and (4) JCPyV S269F-VP1 VLPs. The last two carry mutations in VP1 
which have been found exclusively in patients with PML. These amino acid substitutions 
close to binding sites for sialic acid structures enable viral interactions with cellular receptors 
and hence viral infectivity. Moreover, both mutants lack the ability to trigger 
hemagglutination which suggests that L55F and S269F mutations may influence the cell 
tropism of JCPyV in human by abrogating the ability to bind to sialylated molecules on a 
variety of peripheral cell types. Therefore we investigated if the distribution and clearance of 
JCPyV L55F-VP1 VLPs and JCPyV S269F-VP1 VLPs are different in comparison to JCPyV wild-
type-VP1 VLPs. 
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In conducted study, we observed distribution of both JCPyV VLPs and BKPyV VLPs mostly in 
the liver, but also at lower level in kidney and spleen. Moreover, liver uptake was 
predominantly observed in liver sinusoidal endothelial cells (LSECs). Surprisingly, there was 
no significant difference in tissue distribution between wild-type JCPyV VLPs and JCPyV VLP 
mutants (L55F and S269F). Also, the blood half-time was similar for all of them. With a view 
to the lack of sialic acid binding activity in mutant VLPs, this indicates involvement of other 
non-sialic acid receptors in cellular uptake. While all types of JCPyV VLPs were almost 
completely removed from the circulation within 10 minutes, it took significantly longer time 
for BKPyV VLPs. This suggests either higher stability of BKPyV VLPs in comparison to 3 
variants of JCPyV VLPs or a rapid saturation of BKPyV binding receptors. Another reason for 
a delay of BKPyV VLPs clearance from the blood could be unspecific interactions of BKPyV 
VLPs with blood factors. To maintain signature scavenging activity LSECs rely on clathrin-
mediated endocytosis. It is also known that in natural host cells BKPyV is internalized via 
caveolin-mediated, whereas JCPyV- via clathrin-mediated endocytosis. This could also 
explain the higher blood half-time for BKPyV VLPs in comparison to JCPyV VLPs.  
Further studies would be required to establish whether JCPyV or BKPyV uptake in LSECs 
would lead to destruction of all internalized virus particles. Additionally, a better 
understanding of LSEC-mediated polyomavirus clearance could lead to better understanding 
of development mechanism of polyomavirus-associated diseases. This may also allow to 
develop the strategies to arrest this process for immunocompromised subjects at risk of 
high-level polyomavirus replication. Another important subject would be to investigate 
organ distribution, LSEC uptake and clearance of VLPs preincubated with either murine or 
human antibodies and to compare them with non-preincubated VLPs. 
 
Due to morphological identity with authentic virus, virus-like particles are widely used as an 
antigen to detect virus-specific antibodies. Numerous studies showed that use of VLPs, 
rather than VP1 monomers or pentamers, for detection of specific antibodies makes the 
testing more sensitive and specific. Therefore majority of serological tests, including 
enzyme-linked immunosorbent assays (ELISA) utilize VLPs as the antigen.  
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5.2 Inter- and Intralaboratory Comparison of JC Polyomavirus Antibody Testing 
Using Two Different Virus-Like Particle-Based Assays 
 
Because of more frequent application of immunosuppression, the risk of developing JCPyV- 
and BKPyV-associated diseases (PML for JCPyV and PyVAN and PyVHC for BKPyV) has 
increased drastically in the last decades. The risk of PML development is estimated to be 
100-fold higher for JCPyV-seropositive patients in comparison to JCPyV-seronegatives. Most 
cases of PyVAN and PyVHC have been tested as positive for BKPyV at the moment of disease 
diagnosis. Moreover, positive JCPyV or BKPyV serostatus indicates not only past exposure, 
but also viral persistence which is associated with a risk of high-level viral replication in case 
of immunosuppression. Therefore, investigation of JCPyV and BKPyV infection has been 
receiving significantly more attention. However, correct identification of IgG positive and 
negative results could be problematic due to lack of universal standardized ELISA procedure.  
In conducted study we reviewed and optimized virus-like particle (VLP)-based ELISA for 
JCPyV IgG detection. Moreover we developed the preadsorption inhibition assay in order to 
precisely define JCPyV serostatus for samples with ambiguous ELISA results.  
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Validation and optimization of VLP-based ELISA was performed by investigation of JCPyV- 
specific IgG response in 400 healthy blood donors. The same set of samples was in parallel 
tested in independent ELISA in Helsinki. Comparison of both data sets revealed discordance 
for 10% samples, which showed low IgG activity close to respective cutoffs of the assays. By 
introduction of normalization of results the overall assay performance has improved, 
resulting in decrease of discordance rate. To precisely define JCPyV serostatus for samples 
with discordant ELISA results, we developed a preadsorption inhibition assay. Decrease in 
IgG activity has been measured after preincubation with JCPyV VLPs in solution. The 35% 
decrease in the signal has been determined as the cutoff for the preadsorption ihibition 
assay. Moreover, we also analyzed JCPyV IgG seropositive samples after preadsorption with 
BKPyV VLPs and therefore excluded impact of cross-reactive antibodies in total JCPyV IgG 
signal.  
In conclusion, we confirmed that VLP-based ELISA with normalization step can serve as a 
reliable tool for JCPyV IgG serology. Additionally, the preadsorption assay can help with 
unequivocal determination of JCPyV serostatus for samples with low IgG levels close to 
cutoff. For testing of sera with unknown JCPyV IgG serostatus the following points should be 
taken under consideration: (1) sample should be tested at least in duplicate; (2) 
normalization using reference serum should be always performed - additional quality control, 
when the expected signal for reference serum is known; (3) sample with low IgG activity 
close to cutoff should be additionally tested in preadsorption inhibition assay; (4) training of 
a person performing the testing would be beneficial. 
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5.3 Optimizing JC and BK Polyomavirus IgG Testing for Seroepidemiology 
and Patient Counseling 
 
In the previous study 10% of VLP-based ELISA results were discordant in the interlaboratory 
comparison with results from independent ELISA testing. All of them showed low IgG activity 
against JCPyV VLPs. To avoid misinterpretation of serostatus for samples with low antibody 
responses, we reinvestigated the performance of our optimized VLP-based ELISA by 
investigation of serum sample at 100-, 200- and 400-fold serial dilutions, in contrast to only 
one 400-fold dilution used in the previous study. Moreover, we adapted our ELISA for BKPyV 
IgG detection, by utilizing BKPyV VLPs as a coating antigen.  
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With this study we presented that also BKPyV VLPs can be utilized in our normalized ELISA 
for BKPyV IgG detection. By testing 400 healthy donor samples at 100-, 200 and 400-fold 
dilutions we showed, that 100-fold dilution provides the highest sensitivity for both JCPyV 
and BKPyV testings and no false-negative results. Taking this dilution and supporting it with 
preadsorption inhibition assay might be the most suitable for testing individual patients. 
Although at 200-fold serum dilution sensitivity went down to 98.3% for JCPyV IgG and stayed 
at 100% for BKPyV IgG, the best trade-off between sensitivity and specificity was achieved. 
Thus, 200-fold dilution in normalized VLP-based ELISA might be the most appropriate for 
seroepidemiological studies of large sample size. 400-fold serum dilution might give first 
approximation of high and low JCPyV and BKPyV IgG levels. Of note, specificity was equal to 
100%, whereas sensitivity decreased to 87% - 89%. Depending on the results, preadsorption 
reduction assays could be applied to low-level antibody sear in order to rule out false-
positives. 
Although we showed that normalized ELISA is a specific and sensitive assay for detection of 
antibodies against either JCPyV or BKPyV, officially approved reference serum is needed in 
order to enhance reproducibility and permit clarification of PyV serology potential in clinical 
practice. 
 
In immunocompetent individuals JCPyV or BKPyV infection is not definite and may be 
subclinical or unspecific. Both viruses can cause serious diseases only when immune 
functions are impaired. This applies to immunocompromised patients, including those with 
HIV-AIDS and patients with hematologic malignancies, solid cancers, organ transplantation, 
and autoimmune diseases treated with immunomodulators. Among these patients the risk 
of high-level JCPyV or BKPyV replication, followed by development of PyV-associated disease, 
is higher because their immune control fails to control viral replication. The most common 
disease caused by JCPyV is PML, whereas two most common BKPyV-associated diseases are 
PyVAN and PyVHC. Unfortunately there is currently no specific antiviral therapy for any of 
those and treatment is usually focused on regaining immune functions controlling virus 
replication. Therefore, sensitive and specific testing for antibodies against JCPyV and BKPyV 
in immunocompromised individuals is needed. The following 4 case report studies cover 
examples of immunocompromised individuals undergoing the treatment with different 
immunosuppressive drugs. Normalized ELISA was utilized to investigate their JCPyV and 
BKPyV serostatus in order to support the diagnosis of PyV-associated diseases.  
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5.4 Progressive Multifocal Leukoencephalopathy in Common Variable 
Immunodeficiency: Mitigated Course Under Mirtazapine and Mefloquine 
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5.5 A Case of Primary JC Polyomavirus Infection–Associated Nephropathy 
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5.6 BK Polyomavirus-Specific Cellular Immune Responses Are Age-Dependent 
and Strongly Correlate With Phases of Virus Replication 
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5.7 Diffuse Gastrointestinal Bleeding and BK Polyomavirus Replication in a 
Pediatric Allogeneic Haematopoietic Stem Cell Transplant Patient 
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Our normalized VLP-based ELISA was applied to investigate anti-JCPyV and anti-BKPyV 
antibodies in clinical case studies:  
(1) Patient with definitive diagnosis for PML showed positive JCPyV IgG serostatus, which 
was in line with other PML symptoms including high level of JCPyV DNA detected in 
cerebrospinal fluid (CSF), NCCR mutations characteristic for PML and brain lesions shown by 
magnetic resonance imaging (MRI). However in this case positive JCPyV IgG serostatus might 
be unreliable since the patient has regularly received intravenous immunoglobulins (IvIgG). 
Two years after PML onset, the patient is still alive. 
(2) Asymptomatic JCPyV viral shedding occurs in up to 30% of human population. However, 
only few reports describe JCPyV as a cause of PyVAN. This is the first case report study of 
JCPyV-VAN. Normalized JCPyV VLP-based ELISA was used for detection of anti-JCPyV IgG and 
IgM. Testing has been performed at several time points after kidney transplantation. Young 
boy was clearly seronegative and demonstrated a seroconversion first for IgM and followed 
by IgG, which indicates primary infection. The poor outcome of this case highlights the 
potential importance of JCPyV serostatus in pediatric and adolescent KT recipients. Our case 
underlines the limitations of current guidelines and proves that blood JCPyV DNA findings 
are not reliable. Further studies and better understanding are needed to optimize the 
management of JCPyV-associated nephropathy and the potential role of JCPyV and BKPyV 
serology for donor and recipient.  
(3) Testing of 122 immunocompetent and 63 immunocompromised patients demonstrated 
age dependency of BKPyV IgG level, with the highest values between 20 and 30 years. Also 
maximum levels of specific CD4 T cells has been observed for the same age rang, and 
thereafter progressively decreased to below detection limit in most of the older age groups. 
This correlation suggests an increased vulnerability of older kidney transplant recipients to 
BKPyV-replication. Whereas BKPyV-specific CD4 T cells of immunocompetent individuals 
exhibited a multifunctional phenotype expressing several cytokines in response to 
stimulation, kidney transplant patients with BKPyV-associated complications showed a 
significant loss of multifunctional CD4 T cells. These results indicate the particular need for 
intact T cell functionality to control BKPyV replication. Despite quantitative similarities, 
young adults and patients with complications differed in functional characteristics of BKPyV-
specific immunity. Therefore, cytokine profiling may be important as a tool for 
discrimination of immunologically controlled BKPyV-infection from uncontrolled virus 
replication and therefore could serve as risk predictor of PyVAN development. 
 
124 
 
(4) Pediatric allogeneic hematopoietic stem cell transplant patient was tested as positive for 
BKPyV IgG antibodies, which was in accordance with a significant BKPyV viruria and viremia 
and start of PyVHC. Gastrointestinal complications with bleeding are a significant problem 
after allogeneic HSCT with viral infections including BKPyV. Massive BKPyV viremia has been 
associated with PyVHC which can result in other replication foci including the GI tract. This 
has to be taken under consideration in future studies. 
 
125 
 
 
5.8 Antibody Response to BK Polyomavirus as a Prognostic Biomarker and 
Potential Therapeutic Target in Prostate Cancer 
 
VLPs composed of VP1 and LTag are currently the most common antigens to detect specific 
anti-JCPyV and anti-BKPyV antibodies. Both proteins are good ELISA antigen candidates due 
to their immunogenicity and capability to stimulate B cell responses. Therefore we decided 
to use both proteins as antigens in ELISA for screening of BKPyV IgG response among 226 
patients undergoing radical prostatectomy from primary prostate cancer. With this, we 
investigated whether the preoperative antibody responses to BKPyV LTag or VP1 were 
associated with the risk of biochemical recurrence of prostate cancer. 
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Testing of patients undergoing radical prostatectomy from primary prostate cancer for 
antibodies against BKPyV LTag and VP1 revealed no association between BKPyV VP1 
antibody level and the risk of prostate cancer recurrence. That was in contrast to anti-LTag 
response correlating with the clinical course of prostate cancer patients after radical 
prostatectomy. Due to oncogenic activity of LTag the increased antibody activity against 
LTag would be expected in cases with high risk of biochemical recurrence. This study 
underlines how important is the choice of appropriate antigen in order to give a correct 
answer to assigned study question. 
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6 Discussion 
 
Although JCPyV and BKPyV infections are usually asymptomatic, both viruses can lead to 
serious diseases in patients with immune response impairment. JCPyV can cause progressive 
multifocal leukoencephalopathy (PML) in patients with HIV-AIDS, malignancies or 
autoimmune diseases under immunosuppressive treatment. Whereas increased BKPyV 
replication can induce polyomavirus-associated nephropathy (PyVAN) in kidney transplant 
recipients or hemorrhagic cystitis (PyVHC) after allogeneic hematopoietic stem cell 
transplantation. Due to more frequent application of immunosuppression, the risk of 
developing these diseases has increased drastically in the last few decades. Therefore, 
investigation of JCPyV and BKPyV infection has been receiving significantly more attention. 
This thesis addresses the following aspects: 
1. Use of virus like particles as a tool to study the fate and innate immune response to 
primary JCPyV and BKPyV viremia. 
2. Optimization of VLP-based ELISA for JCPyV and BKPyV IgG detection. 
3. Development of preadsorption inhibition assay in order to precisely define JCPyV and 
BKPyV IgG serostatus for samples with ambiguous ELISA result. 
4. Application of optimized JCPyV/BKPyV VLP-based ELISA in clinical case studies. 
5. Investigation of prognostic value of ELISA utilizing either BKPyV VP1 VLPs or BKPyV LTag as 
antigen. 
Clinical models of JCPyV and BKPyV infection are currently lacking. Their initial infection 
route and organ distribution are also not understood. Following respiratory or 
gastrointestinal transmission, JCPyV and BKPyV colonize the renourinary tract - the major 
site of persistence. To reach the renourinary tract, a viremic phase has been postulated, but 
the fate of JCPyV and BKPyV primary viremia is currently unknown. Like most of HPyVs, 
JCPyV and BKPyV replication is highly specific to the human host, which precludes studies of 
virus replication in animal models. However, the α2,6-linked and α2,3-linked sialic acid 
receptors used by JCPyV and BKPyV, respectively, are widespread in vertebrates, including 
mice. Therefore we decided to study the fate of BKPyV and JCPyV VLPs in blood and their 
cellular site of uptake in a mouse model (Simon-Santamaria et al., p. 54). Four different VLPs 
were used: (1) JCPyV wild-type-VP1 VLPs; (2) BKPyV wild-type-VP1 VLPs; (3) JCPyV L55F-VP1 
VLPs and (4) JCPyV S269F-VP1 VLPs. The latter two VLPs carry mutations in major capsid 
protein 1 (VP1) which have been found exclusively in patients with PML (97). These 
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substitutions affect amino acids located at or close to binding sites for sialic acid structures, 
which enables viral interactions with cellular receptors and hence viral infectivity (98). 
Moreover, both mutants, in contrast to wild-type VLPs, lack the ability to trigger 
hemagglutination. This might suggest that L55F and S269F mutations may influence the cell 
tropism of JCPyV in human by abrogating the ability to bind to sialylated molecules on a 
variety of peripheral cell types, but retain the ability to bind CNS glial cells (99). By using 
above-mentioned VLPs, which are a good model system for virions, we observed that the 
effective clearance of both JCPyV and BKPyV takes place in liver sinusoidal endothelial cells 
(LSECs) (2, 355). Some differences between the JCPyV VLPs and BKPyV VLPs clearance 
patterns were observed. While JCPyV VLPs were almost completely removed from the 
circulation within 10 minutes, it took significantly longer time for BKPyV VLPs, suggesting 
either higher stability of BKPyV VLPs in comparison to 3 variants of JCPyV VLPs, a rapid 
saturation of BKPyV binding receptors or interaction of BKPyV VLPs with blood factors, 
delaying the blood clearance. Moreover, in natural host cells BKPyV is reported to be 
internalized via caveolin-mediated endocytosis whereas JCPyV via clathrin-mediated 
endocytosis (356). This could also be an explanation of our results, because LSECs rely on 
clathrin-mediated endocytosis to maintain their signature scavenging activity. Despite this 
efficient clearance mechanism, VLPs still reached the kidney and were efficiently taken up in 
some microvessels of renal medulla and the spleen marginal zone reticuloendothelium, 
suggesting a role in viremic organ tropism. It suggests that LSECs may play a key role in the 
mostly asymptomatic course of primary JCPyV and BKPyV infection, leaving only little virus 
to escape and reach the renal medulla and possibly the spleen, an important site of viruses 
persistence. For two PML mutants, L55F and S269F, blood half-life and tissue distribution of 
VLPs were similar to the wild-type VLPs, which indicate the involvement of non-sialic acid 
receptors in cellular uptake. 
Further studies would be require to establish whether JCPyV or BKPyV uptake in LSECs 
would lead to destruction of all internalized virus particles, or allow for endosomal escape 
and intracellular replication of a fraction of the internalized virions. Additionally, a better 
understanding of LSEC-mediated polyomavirus clearance may shed light into the role of 
these cells in the development of polyomavirus-associated diseases. This may also allow 
developing the strategies to harness this process for immunocompromised subjects at risk of 
high-level polyomavirus replication. 
In the next part of the thesis we focused on validation and optimization of virus-like particle 
(VLPs)-based testing for JCPyV- and BKPyV-specific IgG (Kardas et. al., p. 72).  
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The diagnosis of JCPyV or BKPyV infection can employ detection of either viral DNA or 
specific antiviral antibodies. However, it has been shown previously that in some cases DNA 
detection is not enough sensitive indicator of viral infection, including examples of PML 
patients with no detectable JCPyV DNA in urine and blood samples or individuals with 
undetectable urinary JCPyV shedding, albeit with JCPyV-specific antibodies (2, 310, 357, 
358). Therefore JCPyV and BKPyV serology has become the critical first choice analysis to 
classify patients exposed to both viruses. It is also receiving increasing attention as potential 
predictors of the risk of polyomavirus-associated diseases. Despite the obvious advantages 
of neutralization, ELISA has become the most common serological testing for detection of 
JCPyV- and BKPyV-specific antibodies. It usually uses viral capsid protein 1 (VP1) as the 
antigen for detection of specific anti-JCPyV and anti-BKPyV antibodies. VP1 can be used in 
the form of monomers, pentamers or VLPs (2). However, it has been confirmed that utilizing 
VLPs in ELISA makes the assay more sensitive and specific in comparison to ELISA using VP1 
either in monomer or pentamer form (2, 325, 359).  
The positive JCPyV or BKPyV serostatus indicates not only past exposure, but also viral 
persistence and the associated risk of high-level replication in case of immune function 
impairment, resulting eventually in PyV disease (71, 90, 317, 360). Unfortunately correct 
identification of IgG positive and negative results could be problematic due to lack of 
universal standardized ELISA procedure, differences in antigen preparation and serum 
dilutions, empirically derived cutoffs, and lack of WHO-approved international reference 
serum. 
During validation and optimization of virus-like particle (VLPs)-based testing for JCPyV- and 
BKPyV-specific IgG we demonstrated that although no statistically significant differences in 
intraassay and interassay variability were revealed for JCPyV serology of 400-fold diluted 
sera from 400 healthy donors, qualitative differences were seen in the identification of the 
individual JCPyV serostatus (Kardas et. al., p. 72). By interlaboratory comparison of our ELISA 
result with results obtained in independent VLP-based assay in Helsinki, discordant JCPyV 
IgG results have been observed for 10% samples. The discordance resulted from sera with a 
low IgG activity close to the cutoffs of both assays. Performance of normalization to a 
reference serum was shown to improve the overall assay performance by reducing the rate 
of discordance. Since the discordances in this low OD range could still be caused by false-
positive (e.g. cross-reactive) or false-negative (e.g. low IgG) results, we developed 
preadsorption assay to better verify the serostatus of discordant samples. By reduction in 
JCPyV IgG activity after preincubation with JCPyV VLPs and cutoff of 35%, we were able to 
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solve the serostatus for previously discordant samples. Importantly, we also excluded BKPyV 
antibody cross-reactivity by testing JCPyV IgG positive sera in preadsorption with BKPyV 
VLPs and observing IgG inhibition at low 8% level. In conclusion, our findings demonstrate 
that serological assays for JCPyV IgG need to take under consideration whether 
epidemiological questions or individual risk assessments are to be addressed. We confirmed 
that VLP-based ELISA with normalization step can serve as a reliable tool for JCPyV IgG 
serology. Additionally, the preadsorption assay can help with unequivocal determination of 
JCPyV serostatus for samples with low IgG levels. 
Further, we reinvestigated the performance of our normalized VLP-based assay and adapted 
it to BKPyV IgG detection (Kardas et al., p. 82). To find the best testing conditions, each 
serum from 400 healthy blood donors was tested at 100-, 200- and 400-fold dilutions. We 
observed that 1:200 dilution provided the best trade-off between sensitivity and specificity 
with respective values being 98.3% and 97.5% for JCPyV IgG, and 100% and 98% for BKPyV 
IgG. Thus, the 1:200 dilution in the normalized ELISA format might be the most appropriate 
for seroepidemiological studies when large sample size is considered. The 1:100 dilution 
provided the highest sensitivity for JCPyV and BKPyV IgG detection and no false-negative 
results. If combined with preadsorption reduction for confirmation, this approach might be 
the most suitable for individual patient counseling. The 1:400 dilution can provide first 
approximation of higher and lower JCPyV- and BKPyV-specific IgG levels. As relative antibody 
levels and their change over time should be explored in clinical settings, this dilution seems 
to be appropriate for specific clinical setting including intrathecal antibodies or pretransplant 
serology (105, 361, 362). With this study we showed that for seroepidemiology studies, 
normalized JCPyV and BKPyV IgG ELISA at 1:200 serum dilution provides optimal sensitivity 
and specificity with the lowest false-positive and false-negative rate. However, for individual 
risk assessment, 100-, 200-, and 400-fold dilutions combined with preadsorption for low-
reactive sera might be the most appropriate. 
Next, our normalized VLP-based ELISA was applied to investigate JCPyV and BKPyV 
seroprevalence in clinical case studies: (1) positive JCPyV IgG serostatus for PML patient was 
in line with other PML symptoms including high level of JCPyV DNA detected in 
cerebrospinal fluid (CSF), NCCR mutations characteristic for PML and brain lesions shown by 
magnetic resonance imaging (MRI) (Kurmann et al., p. 90); (2) positive JCPyV IgG and IgM 
and negative BKPyV IgG and IgM serostatus for a boy after kidney transplantation confirmed 
the diagnosis of JCPyV-associated nephropathy (Lautenschlager et al., p. 99); (3) testing of 
122 immunocompetent and 63 immunocompromised patients demonstrated age 
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dependency of BKPyV IgG level, with the highest values between 20 and 30 years (Schmidt 
et al., p. 106); (4) positive BKPyV IgG serostatus for serum samples from pediatric allogeneic 
hematopoietic stem cell transplant patient was in accordance with a significant BKPyV 
viruria and viremia and start of PyVHC (Koskenvuo et al., p. 119). 
As a conclusion of this part of the thesis, our findings demonstrate that serological assays for 
JCPyV and BKPyV need to take into account whether epidemiological questions or individual 
risk assessments need to be addressed. Testing of serum sample in 100-, 200-, and 400-fold 
dilution series in a normalized VLP ELISA provides a convenient determination of JCPyV and 
BKPyV-specific antibody status and levels. Additionally, preadsorption assay could be applied 
to low-level antibody sera in order to rule out false-positives, and therefore avoid 
unnecessary withholding of an effective treatment option, and false-negatives, for better 
estimation of the risk of PyV-associated diseases.  
For future investigation of unknown sera samples the following conditions are suggested to 
be fulfilled: (1) sample should be tested in at least duplicates to avoid technical errors; (2) 
every ELISA should include reference serum for results normalization; (3) samples with low 
IgG activities should be additionally tested in preadsorption assay. Quality assessment 
programs with appropriate training for laboratory technicians would be recommended in 
order to globally standardize the ELISA performance and antigen preparation. Moreover, 
reference sera approved by WHO might significantly enhance testing reproducibility and 
permit clarification of potential role of PyV serology in clinical practice. 
T cell immunity to polyomaviruses has been studied mostly for large T antigen (LTag) and 
capsid protein VP1 (285-297). Both proteins are good ELISA antigen candidates due to their 
immunogenicity and capability to stimulate B cell responses (298). Therefore we decided to 
use both proteins as antigens in ELISA for screening of BKPyV IgG response among 226 
patients undergoing radical prostatectomy from primary prostate cancer (Keller et al., p. 
125). We evaluated whether the preoperative antibody responses to BKPyV LTag and VP1 
were associated with the risk of biochemical recurrence of prostate cancer. No evidence for 
an association between BKPyV VP1 serostatus and the risk of prostate cancer recurrence 
was observed. However, an antibody response to LTag was associated with the clinical 
course of prostate cancer patients after radical prostatectomy. Due to the fact that LTag 
may lead to the oncogenic transformation of BKPyV infected glandular prostate cells, an 
increased antibody activity against this oncogenic protein would be expected in cases with 
high risk of biochemical recurrence. In this study we revealed that the preoperative LTag 
serology may be a valuable biomarker for a prediction of favorable prostate cancer 
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prognosis after radical prostatectomy. Finally, this study underlines how important is to 
choose an antigen which will be adequate to assigned study question.  
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